Page last updated: 2024-11-04

labetalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Labetalol is a nonselective beta blocker with alpha-1 blocking activity. It is used to treat high blood pressure (hypertension). Labetalol was first synthesized in 1974 and is now a widely prescribed medication. It is available as an oral tablet and an intravenous solution. Labetalol works by blocking the effects of adrenaline and noradrenaline on the heart and blood vessels. This reduces heart rate and blood pressure. It is important to note that Labetalol is not appropriate for everyone. It should not be used by people with certain medical conditions, such as asthma, bradycardia, or heart block. It is also not recommended for use during pregnancy. Studies on Labetalol are ongoing to explore its potential use in treating other conditions, such as heart failure and migraine headaches. Labetalol is a well-tolerated drug, but side effects can occur. These may include dizziness, fatigue, and headache. Labetalol is a valuable medication for treating high blood pressure and other conditions. It is important to use it as prescribed by a doctor.'

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3869
CHEMBL ID429
CHEBI ID6343
CHEBI ID167638
SCHEMBL ID4582
MeSH IDM0012098

Synonyms (115)

Synonym
AC-18747
labetalolum
CHEBI:6343 ,
CHEBI:167638
BRD-A07440155-003-05-6
KBIO1_000474
DIVK1C_000474
normodyne
trandate
2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide
SPECTRUM_001607
BSPBIO_000154
benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-
albetol
labetalolum [inn-latin]
hsdb 6537
ibidomide
ah 5158
2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide
einecs 253-258-3
labetalol [inn:ban]
PRESTWICK3_000277
SPECTRUM5_001010
LOPAC0_000687
bdbm25758
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
AB00053659
C07063
labetalol
36894-69-6
DB00598
5-(1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
labetolol
3-carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
KBIO2_004655
KBIOSS_002087
KBIO2_007223
KBIO2_002087
KBIO3_002642
KBIOGR_000727
SPBIO_000905
PRESTWICK1_000277
SPECTRUM2_000863
NINDS_000474
SPECTRUM3_001581
PRESTWICK0_000277
SPECTRUM4_000184
SPBIO_002373
IDI1_000474
BPBIO1_000170
PRESTWICK2_000277
BSPBIO_003142
NCGC00089800-02
apo-labetalol
NCGC00015595-06
L001344
ah-5158a free base
sch-15719w free base
CHEMBL429
D08106
labetalol (inn)
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
2-hydroxy-5-(1-hydroxy-2-((4-phenylbutan-2-yl)amino)ethyl)benzamide
A823444
CCG-204772
NCGC00015595-07
NCGC00015595-04
NCGC00015595-03
unii-r5h8897n95
r5h8897n95 ,
ec 253-258-3
FT-0670696
AKOS015908406
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzene-1-carboximidic acid
gtpl7207
labetalol [inn]
labetalol [vandf]
labetalol [who-dd]
labetalol [hsdb]
labetalol [mi]
SCHEMBL4582
benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-
normodyne (salt/mix)
amipress (salt/mix)
2-hydroxy-5-(1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl)benzamide
labetalol hydrochloride (salt/mix)
trandate (salt/mix)
3-carboxamido-4-hydroxy-.alpha.-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
Q-201273
AB00053659_13
DTXSID2023191 ,
mfcd00242941
SBI-0050665.P003
NCGC00015595-12
DS-4652
32780-40-8
Q958087
BRD-A07440155-003-16-3
labetolol;albetol;normodyne;apo-labetalol
BCP31095
SDCCGSBI-0050665.P004
NCGC00015595-19
36894-69-6 (free base)
NCGC00015595-14
C74903
HY-121383
CS-0081835
ah5158;sch-15719w free base
labetalolum (inn-latin)
dtxcid603191
5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide
labetalolo
c07ag01
kabetalol
EN300-1272609

Research Excerpts

Overview

Labetalol is a drug used in the treatment of hypertensive disorders of pregnancy (HDP) It is a good alternative drug to control hypertensive response during emergence from anesthesia for post-craniotomy.

ExcerptReferenceRelevance
"Labetalol is a drug used in the treatment of hypertensive disorders of pregnancy (HDP). "( Influence of the maternal use of labetalol on the neurogenic mechanism for cerebral autoregulation assessed by means of NIRS.
Caicedo, A; Lemmers, P; Naulaers, G; Thewissen, L; Van Bel, F; Van Huffel, S; Varon, C, 2014
)
2.13
"Labetalol is a reasonable choice for treatment of severe or non-severe hypertension in pregnancy. "( Labetalol for hypertension in pregnancy.
Cao, V; Koren, G; Magee, LA; Namouz-Haddad, S; von Dadelszen, P, 2015
)
3.3
"Labetalol is a good alternative drug to control hypertensive response during emergence from anesthesia for post-craniotomy."( An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015
)
1.42
"Labetalol is a commonly used agent for perioperative hypertension in renal transplant recipients. "( Labetalol-induced hyperkalemia in renal transplant recipients.
Jordan, M; McCauley, J; Murray, J; Scantlebury, V; Shapiro, R; Vivas, C,
)
3.02
"Labetalol is a widely used drug for the management of hypertension, which is preferably administered by the oral route despite its low bioavailability. "( Labetalol absorption kinetics: rat small intestine and colon studies.
Abushammala, I; Casabó, VG; Garrigues, TM; Martín-Villodre, A; Nácher, A, 2006
)
3.22
"Labetalol is an effective antihypertensive medication frequently used to treat systemic hypertension in acute care settings, including the management of hypertension associated with a subarachnoid hemorrhage. "( Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage.
Baker, AJ; Choi, M; Hare, GM; Jivraj, S; Mazer, CD, 2006
)
2.03
"Labetalol is a mixture of four isomers. "( Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
Baum, T; Glennon, J; Gold, EH; Pula, KK; Sabin, CS; Sybertz, EJ; Vliet, GV, 1981
)
1.96
"1 Labetalol is an effective agent in essential hypertension as documented in open studies and controlled studies in which its efficacy has been compared with both placebo and a variety of other anti-hypertensive drugs. "( Labetalol in essential hypertension.
Breckenridge, A; Maciver, M; Orme, M; Serlin, MJ, 1982
)
2.43
"Labetalol is an investigational alpha- and beta- adrenoreceptor antagonist. "( Labetalol: an alpha- and beta-blocker.
Conner, CS,
)
3.02
"Labetalol is a safe and effective treatment for a rapid blood pressure reduction in hypertensive emergencies."( Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies.
Flamenbaum, W; Freis, ED; Langford, HG; Michelson, EL; Poland, MP; Vidt, DG; Vlachakis, ND; Wallin, JD; Wilson, DJ, 1983
)
1.37
"Labetalol is a unique antihypertensive agent which induces both alpha- and beta-blockade."( Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
Lund-Johansen, P, 1984
)
1.22
"Labetalol is an orally active adrenoreceptor-blocking drug which is a competitive antagonist of both alpha- and beta-adrenoreceptor sites. "( Labetalol in essential hypertension.
Hamet, P; Hoffman, B; Kuchel, O; Larochelle, P; McKenzie, J; Mitenko, P; Ogilvie, RI; Ruedy, J,
)
3.02
"Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. "( Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
Bloomfield, SS; MacCarthy, EP,
)
3.02
"Labetalol is a new adrenergic antagonist with both alpha- and beta-blocking effects. "( Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease.
Burford, JG; Conrad, SA; George, RB; Kinasewitz, GT; Manocha, K, 1983
)
2.1
"Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. "( Labetalol.
Carter, BL, 1983
)
3.15
"Labetalol is a new adrenergic antagonist with both alpha- and beta-blocking effects. "( Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease.
Chetty, KG; Light, RW; Stansbury, DW, 1983
)
2
"Labetalol is a safe and effective treatment for patients with mild hypertension."( Monotherapy with labetalol in the treatment of mild hypertension: a double-blind study.
Davidov, ME; Maloy, J; Medakovic, M; Moir, GD; Poland, MP, 1983
)
1.33
"Labetalol is a safe and effective step II drug when added to hydrochlorothiazide for the treatment of patients with moderate to moderately severe hypertension."( Step II treatment with labetalol for essential hypertension.
Bloomfield, SS; Gantt, CL; Lucas, CP; Medakovic, M; Poland, MP, 1983
)
1.3
"Labetalol appears to be a suitable alternative to the direct vasodilating agents in the management of patients with severe hypertension and hypertensive emergencies."( Intravenous labetalol in the management of severe hypertension and hypertensive emergencies.
Cressman, MD; Gifford, RW; Moore, WS; Vidt, DG; Wilson, DJ, 1984
)
1.37
"Labetalol is an alpha- and beta-blocking agent commonly used in anti-hypertensive therapy. "( Analgesic effect of peridural labetalol in the treatment of cancer pain.
Fanzago, E; Gagliardi, M; Margaria, E; Palieri, L; Treves, S, 1983
)
2
"Labetalol (Trandate) is a new antihypertensive agent with both alpha- and beta-adrenoceptor blocking properties. "( Labetalol in the treatment of hypertension in patients with normal and impaired renal function.
Berg, KJ; Nilsen, OG; Walstad, RA; Wessel-Aas, T, 1982
)
3.15
"Labetalol, which is a combined alpha- and beta-blocking agent, reduces mean blood pressure levels at all times."( Effects of treatment on circadian rhythms of blood pressure.
Balasubramanian, V; Mann, S; Millar-Craig, MW; Raftery, EB, 1981
)
0.98
"Labetalol is an effective antihypertensive agent, but side effects are common and it has few advantages over drugs presently available."( Use of labetalol in moderate to severe hypertension.
Hua, AS; Kincaid-Smith, P; Macdonald, I; Thomas, GW; Whitworth, JA; Woo, KT, 1980
)
1.44
"Labetalol is an effective drug in controlling blood pressure and does not adversely affect the UAFVW."( Labetalol therapy in pregnancy induced hypertension: the effects on fetoplacental circulation and fetal outcome.
Bjornsson, S; Calder, AA; Mahmoud, TZ, 1993
)
2.45
"1Labetalol is a new compound with antagonistic effects at both alpha- and beta-adrenoreceptor sites. "( Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
Hänel, B; Hansson, L, 1976
)
2.61
"Labetalol is an orally active adrenoceptor blocking drug which is a competitive antagonist at both alpha- and beta-adrenoceptor sites. "( Labetalol: a review of its pharmacology and therapeutic use in hypertension.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978
)
3.14
"Labetalol seems to be an effective substitute for the beta-blocker plus hydrallazine therapy."( Labetalol in the treatment of hypertensive renal patients.
Craswell, PW; De Voss, K; Williams, JG, 1978
)
2.42
"Labetalol is a useful hypotensive drug with effect similar to that of a combination of a beta-adrenoceptor blocking drug and a vasodilator."( Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study.
Barnett, AJ; Guest, C; Kalowski, S, 1978
)
2.42
"Labetalol is a drug possessing both alpha and beta adrenergic receptor blocking properties. "( Circulatory effects of labetalol during halothane anaesthesia.
Arthur, GR; Buckley, FP; Drummond, GB; Littlewood, DG; Macrae, WR; Scott, DB, 1978
)
2.01
"6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma."( Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.
Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976
)
1.04
"1. Labetalol (AH 5158) is a new drug which has both alpha- and beta-adrenoreceptor antagonist activity. "( Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo.
Armstrong, B; Beilin, LJ; Nassim, M; Pugsley, D, 1976
)
1.1
"Labetalol is a safe and effective antihypertensive in patients with hypertension associated with chronic renal disease."( The short term effects of oral labetalol in patients with chronic renal disease and hypertension.
Catto, GR; Edward, N; Gemmell, HG; Innes, A; Smith, FW, 1992
)
1.29
"As labetalol is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of alpha and beta receptor actions), the combination of RR and SR may be a valuable substitute for labetalol in the treatment of systemic hypertension."( The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.
Latini, R; Mennini, T; Riva, E, 1991
)
1.04
"Labetalol itself is an alpha 1-antagonist but dilevalol, which has negligible affinity for alpha-receptors, exerts its vasodilator effect via beta 2-agonism."( Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly, R; Macphee, GJ, 1991
)
1.23
"Labetalol is a relatively new and unique hypotensive agent that has both alpha- and beta-adrenoceptor blocking properties. "( The hemodynamics and clinical effects of labetalol in hypotensive anesthesia.
Chan, KH; Chang, WK; Choa, CH; Lee, TY; Lin, YF; Liu, K; Tang, GJ, 1990
)
1.99
"Labetalol appears to be an effective and safe agent to use in decreasing hypertension, tachycardia, and possibly arrhythmias in high-risk medical patients with cardiovascular disease undergoing ECT."( Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients.
Cooper, R; Gladson, M; Knos, G; Markwalter, H; Morris, R; Stoudemire, A; Sung, YF, 1990
)
2.44
"Labetalol is an alpha 1- and beta-adrenergic antagonist currently used in the treatment of hypertension. "( Effects of age on the elimination of labetalol.
Rocci, ML; Sirgo, MA; Valiquett, T, 1989
)
1.99
"Labetalol appears to be an effective agent in the management of mild to moderate pregnancy-induced hypertension."( The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension.
Broughton Pipkin, F; Pickles, CJ; Symonds, EM, 1989
)
1.23
"Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties."( Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
Benfield, P; Goa, KL; Sorkin, EM, 1989
)
2.44
"Labetalol is a non-selective beta-adrenoceptor antagonist agent with added alpha 1-adrenergic blocking properties, beta 2-stimulating action, and direct vasodilatory activity. "( Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study.
Charlap, S; Frishman, WH; Shapiro, W, 1989
)
3.16
"Labetalol is an antihypertensive agent with combined alpha- and beta-blocking properties that has been used to manage patients with suspected pheochromocytomas."( Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues.
Fig, LM; Khafagi, FA; Mallette, S; Shapiro, B; Sisson, JC, 1989
)
2.44
"Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites. "( Current status of labetalol, the first alpha- and beta-blocking agent.
Kanto, JH, 1985
)
2.05
"Labetalol is a competitive inhibitor of alpha- and beta-adrenergic receptors and has an antihypertensive action. "( Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery.
Halperin, JL; Kupersmith, J; Litwak, RS; Mindich, BP; Reder, RF; Rothlauf, EB, 1986
)
2.12
"Labetalol is an antihypertensive agent with beta-adrenoreceptor and alpha-adrenoreceptor blocking properties."( Labetalol protects against the potentiation by propranolol of the bronchospasm to norepinephrine in guinea-pigs.
Kreutner, W; Rizzo, C, 1987
)
2.44
"Labetalol appears to be a useful drug for treating the hypertensive heart and its many complications."( Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
Frishman, WH, 1988
)
1.36
"Labetalol is an effective agent in improving exercise tolerance in normotensive patients with stable exertional angina pectoris, with an efficacy similar to that of nifedipine."( Labetalol in the treatment of stable exertional angina pectoris: a comparison with nifedipine.
Crake, T; Fox, K; Mulcahy, D; Wright, C, 1988
)
2.44
"Thus labetalol would appear to be an effective antianginal agent."( Labetalol in normotensive patients with angina pectoris.
Fox, K; Quyyumi, AA, 1988
)
2.17
"Labetalol is a combined alpha- and beta-adrenoreceptor blocking agent. "( Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics.
Chauvin, M; Deriaz, H; Viars, P, 1987
)
2.01
"Thus labetalol is an effective agent in the treatment of angina pectoris."( Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo.
Fox, KM; Mockus, L; Quyyumi, AA; Shackell, M; Sutton, GC; Wright, C, 1985
)
0.93
"Labetalol is a competitive, nonselective antagonist of both beta 1 and beta 2 adrenoceptors. "( Concomitant therapy with labetalol and hydrochlorothiazide in moderate to moderately severe essential hypertension.
Kalbfleisch, JH; Kochar, MS; Tyson, J, 1985
)
2.02
"Labetalol is a unique alpha- and beta-adrenergic-receptor blocking agent that has recently been approved for the treatment of hypertensive emergencies and urgencies. "( Intravenous labetalol in the emergency treatment of hypertension.
Vidt, DG, 1985
)
2.09

Effects

Labetalol has an irreplaceable role in treating Hypertensive disorders of pregnancy (HDP), a common disease during pregnancy with a prevalence of 5.2-8.2%. It has a unique and profound effect on the IOP of rabbits, in contrast to pure beta-adrenergic blockers which have little or no effect in this animal.

Labetalol has a hemodynamic profile which makes it an attractive agent for treating myocardial ischemia. It has been used to treat 163 patients at the Dunedin Hypertension Clinic for periods up to 6.5 y.

ExcerptReferenceRelevance
"Labetalol has an irreplaceable role in treating Hypertensive disorders of pregnancy (HDP), a common disease during pregnancy with a prevalence of 5.2-8.2%. "( Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023
)
2.58
"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1)."( Elimination kinetics of labetalol in severe renal failure.
Bailey, RR; Ferry, DG; Wood, AJ, 1982
)
1.13
"Labetalol has a unique and profound effect on the IOP of rabbits, in contrast to pure beta-adrenergic blockers which have little or no effect in this animal. "( Ocular hypotensive action of labetalol.
Leopold, IH; Murray, DL, 1979
)
1.99
"Labetalol has a hemodynamic profile which makes it an attractive agent for treating myocardial ischemia."( Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
Frishman, WH, 1988
)
1.36
"Labetalol has an irreplaceable role in treating Hypertensive disorders of pregnancy (HDP), a common disease during pregnancy with a prevalence of 5.2-8.2%. "( Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023
)
2.58
"Labetalol has been studied to a lesser extent and may have prolonged cardiovascular effects."( Beta-blocking agents during electroconvulsive therapy: a review.
Birkenhäger, TK; Boere, E; Groenland, TH; van den Broek, WW, 2014
)
1.12
"Labetalol has equivalent efficacy to diltiazem. "( An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015
)
2.15
"Labetalol has been used in patients with severe renal impairment and a number of studies suggest that it may now be the drug of choice in raised blood pressure of pregnancy."( Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Prichard, BN, 1984
)
0.99
"Labetalol has been successful in treating hypertension, and few side effects have been reported, although there have been cases of muscle pain during treatment. "( Labetalol-induced toxic myopathy.
Kissin, E; Rosenthal, T; Sarova, I; Teicher, A, 1981
)
3.15
"1 Labetalol has been used to treat 163 patients at the Dunedin Hypertension Clinic for periods up to 6.5 y, and of 128 patients in a New Zealand multicentre study for 2 yr. "( Review of long-term treatment with labetalol.
Simpson, FO; Waal-Manning, HJ, 1982
)
1.26
"1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension. "( Comparison of labetalol and propranolol in hypertension.
Bulpitt, CJ; Butler, AG; Husaini, MH; Nicholls, DP; Stephens, MD, 1980
)
1.34
"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1)."( Elimination kinetics of labetalol in severe renal failure.
Bailey, RR; Ferry, DG; Wood, AJ, 1982
)
1.13
"Labetalol has been used in 83 patients with severe hypertension resistant to a wide number of drugs. "( Long-term experiences with labetalol.
Adam, W; Hodgson, M; Morgan, T; Myers, J; Waga, S, 1980
)
2
"Labetalol has several advantages over pure beta-blocking drugs and offers an alternative in managing hypertension that is difficult to control."( Labetalol and other agents that block both alpha- and beta-adrenergic receptors.
Pearce, CJ; Wallin, JD,
)
3.02
"Labetalol has been previously shown to cause significant maternal and fetal metabolic effects in pregnant sheep after maternal administration. "( Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration.
Abbott, FS; Axelson, JE; Doroudian, A; Hall, C; Kwan, E; Rurak, DW; Wright, MR; Yeleswaram, K, 1993
)
1.96
"Labetalol has a unique and profound effect on the IOP of rabbits, in contrast to pure beta-adrenergic blockers which have little or no effect in this animal. "( Ocular hypotensive action of labetalol.
Leopold, IH; Murray, DL, 1979
)
1.99
"1 Labetalol has been used as medical treatment in five patients with phaeochromocytoma. "( Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.
Brown, JJ; Lever, AF; Robertson, AS; Robertson, JI; Rosei, EA; Trust, PM, 1976
)
1.21
"Labetalol has been compared with propranolol and placebo for the treatment of mild to moderate hypertension (150/100 to 189/114 mmHg), in a double-blind cross-over trial with three 10 week treatment periods."( Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo.
Armstrong, B; Beilin, LJ; Nassim, M; Pugsley, D, 1976
)
1.2
"Labetalol has been advocated to rapidly decrease blood pressure in preeclamptic women and to blunt the hemodynamic response to tracheal intubation. "( Maternal and fetal effects of labetalol in pregnant ewes.
Dewan, DM; Eisenach, JC; Mandell, G, 1991
)
2.01
"Labetalol has two asymmetric centers and is used clinically as a mixture of the four possible stereoisomers; APB has one asymmetric center."( Stereospecific gas chromatographic/mass spectrometric assay of the chiral labetalol metabolite 3-amino-1-phenylbutane.
Changchit, A; Gal, J; Zirrolli, JA, 1991
)
1.23
"Labetalol has no effect on renal blood flow, glomerular filtration rate, plasma electrolyte concentrations, glucose tolerance, lipoprotein cholesterol ratio, renin-angiotensin-aldosterone system, uric acid levels, or on platelet aggregation."( Labetalol in the treatment of angina pectoris.
Kanto, JH, 1987
)
2.44
"5. Labetalol has little tocolytic effect on human myometrium in vitro."( The effect of labetalol on contractility of human myometrial preparations.
Angilivilayil, C; Ibrahim, M; Lunell, NO; Moberger, B; Thulesius, O, 1987
)
1.15
"Labetalol has a hemodynamic profile which makes it an attractive agent for treating myocardial ischemia."( Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
Frishman, WH, 1988
)
1.36

Actions

Labetalol appears to increase the risk of hyperkalemia in patients after renal transplantation. Labetalol patients had slower heart rates at all time points (P < 0.01).

ExcerptReferenceRelevance
"Labetalol patients had slower heart rates at all time points (P < 0.01)."( CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.
Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, D; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Varon, J, 2011
)
1.32
"Labetalol appears to increase the risk of hyperkalemia in patients after renal transplantation."( Labetalol-induced hyperkalemia in renal transplant recipients.
Jordan, M; McCauley, J; Murray, J; Scantlebury, V; Shapiro, R; Vivas, C,
)
3.02
"labetalol may cause less increase in cardiac size than propranolol."( Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade.
Bjurö, T; Hagman, M; Nyberg, G; Smith, U, 1981
)
0.98
"Labetalol did not cause any significant changes in plasma noradrenaline and adrenaline at rest or during exercise."( Effects of labetalol on plasma renin, aldosterone, and catecholamines in hypertensive patients.
Amery, AK; De Schaepdryver, AF; Fagard, RH; Lijnen, PJ; Moerman, EJ; Reybrouck, TM,
)
1.24
"Labetalol does not cause a bronchospasm in human asthmatics."( Labetalol protects against the potentiation by propranolol of the bronchospasm to norepinephrine in guinea-pigs.
Kreutner, W; Rizzo, C, 1987
)
2.44

Treatment

Labetalol pretreatment appears satisfactory and may be useful in patients with coronary artery disease who have a normal left ventricular ejection fraction. Treatment was appropriately initiated in many cases; however, protocol adherence could greatly improve.

ExcerptReferenceRelevance
"Labetalol hydrochloride treatment for HD in pregnancy can result in presumptive positive urine immunoassays for fentanyl. "( False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report.
Field, TA; Isley, BC; Saia, K; Wanar, A,
)
1.82
"Labetalol treatment was appropriately initiated in many cases; however, protocol adherence could greatly improve. "( Management of Hypertension on the Labor and Delivery Unit: Delivering Care in the Era of Protocols and Algorithms.
Duong, J; Haring, A; Kuhlmann, Z; O'brien, L; Winterton, T, 2018
)
1.92
"Labetalol pre-treatment especially seemed to enhance the effect of subsequent propranolol/hydralazine administration."( Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients.
Donker, AJ; May, JF; ten Berge, BS; van der Veur, E; Wesseling, H, 1982
)
1.35
"5 Labetalol treatment resulted in a significant dose-related delay in detumescence."( A method for monitoring drug effects on male sexual response: the effect of single dose labetalol.
Davies, HJ; Riley, AJ; Riley, EJ, 1982
)
1.04
"Labetalol treatment significantly attenuated the cocaine-induced increases in heart rate and systolic blood pressure."( Effects of labetalol treatment on the physiological and subjective response to smoked cocaine.
Babb, DA; Brown, S; Hatsukami, DK; Pentel, PR; Sofuoglu, M, 2000
)
1.42
"Labetalol-treated pigs exhibited a significant decrease of Bmax and an increase of Kd as compared with brain-dead pigs."( Consequences of labetalol administration on myocardial beta adrenergic receptors in the brain dead pig.
Aubert, N; Burlet, C; Devaux, Y; Mertes, PM; Seguin, C; Siaghy, EM; Ungureanu-Longrois, D; Zannad, F, 2000
)
1.37
"5 Labetalol treatment reduced the variation in systolic BP from the lowest observed quarter-hourly mean as compared with pre-treatment values."( Effect of labetalol on continuous ambulatory blood pressure.
Altman, D; Balasubramanian, V; Mann, S; Millar-Craig, MW; Raftery, EB, 1979
)
1.22
"The labetalol-treated patients were significantly less often above their diastolic BP goal throughout the 24-hour ABPM period (p less than 0.01)."( Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring.
Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA, 1991
)
1.12
"Labetalol pretreatment appears satisfactory and may be useful in patients with coronary artery disease who have a normal left ventricular ejection fraction."( Circulatory responses to thiopentone and tracheal intubation in patients with coronary artery disease. Effects of pretreatment with labetalol.
Brodaty, D; Dubois, C; Fischler, M; Guilmet, D; Melchior, JC; Schlumberger, S; Vourc'h, G, 1985
)
1.19
"Treatment with labetalol was only partially successful in controlling the elevated blood pressure."( Autonomic dysreflexia manifested by severe hypertension.
Assadi, F; Czech, K; Palmisano, JL, 2004
)
0.66
"Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels."( Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trial.
Langford, H; Maloy, J; Maronde, RF; Michelson, EL; Poland, M; Wallin, JD; Wilson, D; Winer, N, 1983
)
0.88
"Pretreatment with labetalol completely blocked adrenaline induced hypokalaemia (3.92-3.95 mmol(mEq)/l)."( Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.
Reid, JL; Struthers, AD; Whitesmith, R, 1983
)
0.81
"Pretreatment with labetalol 10(-4) mol/l inhibited the transient increase in perfusion pressure induced by norepinephrine 3 x 10(-5) mol/l."( The effects of dihydralazine, labetalol and magnesium sulphate on the isolated, perfused human placental cotyledon.
Forman, A; Gregersen, H; Petersen, OB; Skajaa, K; Svane, D, 1994
)
0.9
"3 Treatment with labetalol resulted in satisfactory blood pressure control in 10 of 16 patients in this study but high doses were required, the mean daily dose being 3,091 mg (range 1,200-8,000)."( Labetalol in resistant hypertension.
Daniel, J; Dargie, HJ; Dollery, CT, 1976
)
2.03
"Treatment with labetalol, on the other hand, led to an improvement in respiratory function."( Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986
)
0.61

Toxicity

Labetalol is safe to the fetus and newborn and might offer a better prevention of intrauterine death than methyldopa. The most troublesome side effect of labetall therapy is posture-related dizziness.

ExcerptReferenceRelevance
" Parenteral LD50 showed almost the same values among mice (50 mg/kg iv, 117 mg/kg ip), rats (66 mg/kg iv, 115 mg/kg ip) and rabbits (43 mg/kg iv)."( [On the acute toxicity of labetalol (AH-5158), a combined alpha-and-beta-adrenoceptor-blocking agent (author's transl)].
Fujiwara, S; Katada, H; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1978
)
0.56
"Antihypertensive agents have been associated with adverse reactions that, if unrecognized by health practitioners, may have devastating consequences."( Fatal hepatotoxicity induced by hydralazine or labetalol.
Stumpf, JL, 1991
)
0.54
" Our results demonstrate that dilevalol is as safe and effective as captopril and nifedipine for the treatment of essential hypertension."( [Evaluation of the efficacy and safety of dilevalol in the treatment of essential arterial hypertension].
Bochicchio, T; Carrizosa, J; Herrera-Acosta, J; Pérez-Grovas, HA,
)
0.13
" It is concluded that, although labetalol produces a statistically significant change in PaO2 and PaCO2, this finding has only minor clinical implications and so labetalol remains a safe drug to be used for the induction of deliberate hypotension during middle ear microsurgery."( Safety of labetalol-induced controlled hypotension during middle ear microsurgery.
Adriaensen, H; Boeckx, E; Claes, J; De Hert, S; Van den Heyning, P; Vercauteren, M, 1989
)
0.96
" Adverse hemodynamic and biochemical effects were minor and easily reversible."( The safety of cumulative doses of labetalol in perioperative hypertension.
Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989
)
0.56
" These data indicate that maternal beta-blockade with labetalol is as safe as methyldopa for the fetus and the newborn."( Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.
Breart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1988
)
0.76
" Labetalol is safe to the fetus and newborn and might offer a better prevention of intrauterine death than methyldopa."( [Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. Comparison with methyldopa in a randomized cooperative trial].
Bréart, G; Maillard, F; Papiernik, E; Plouin, PF; Relier, JP, 1987
)
1.45
" Dilevalol, in doses of 200-800 mg/day, is a safe and effective drug for the treatment of patients with mild hypertension."( The safety and efficacy of once-daily dilevalol in patients with mild hypertension: a placebo-controlled study.
Frishman, W; Greenberg, S; Soberman, J, 1987
)
0.27
" The lack of an adverse outcome in this patient does not prove the safety of this technique in patients with liver disease; further studies of this patient group are required."( Safe use of induced hypotension in a patient with cirrhotic liver disease.
Roth, S; Run, S, 1987
)
0.27
" The most troublesome side effect of labetalol therapy is posture-related dizziness."( Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
Bloomfield, SS; MacCarthy, EP,
)
1.85
" The current drug classes are reviewed with respect to dosage guidelines, adverse effects and potential drug-drug interactions."( Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.
Miller, K, 1994
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Aside from patients presenting with ischemic or traumatic brain injury, labetalol was safe to use in this population for hypertensive emergencies and had a satisfactory adverse effect profile."( Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children.
Feig, DI; Moffett, BS; Mott, AR; Thomas, CA; Wagner, JL, 2011
)
0.88
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Both agents appear equally effective and safe for blood pressure control in SAH and ICH during the initial admission hours."( Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage.
Agarwal, S; Badjatia, N; Carpenter, AM; Claassen, J; Lantigua, H; Lee, K; Lesch, C; Li, M; Mayer, SA; Ortega-Gutierrez, S; Reccius, A; Schmidt, JM; Thomas, J, 2013
)
0.65
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" To directly counter these adverse hyperadrenergic effects, the patient was given 10 mg intravenous labetalol, a mixed β- and α-blocker."( Acute Toxicity from Topical Cocaine for Epistaxis: Treatment with Labetalol.
Lange, RA; Laurin, EG; Richards, JR; Tabish, N, 2017
)
0.91
" Vital signs, adverse events and cumulative medication doses were obtained for up to 24 hours while on labetalol."( Safety of high-dose intravenous labetalol in hypertensive crisis.
Brandt, MM; Hecht, JP; Mahmood, SM, 2019
)
1.01
" labetalol hydrochloride with doses greater than 300 mg in 24 hours observed a high rate of bradycardia and hypotension, but the study found that these events rarely caused clinically significant hemodynamic compromise and was not statistically associated with adverse events."( Safety of high-dose intravenous labetalol in hypertensive crisis.
Brandt, MM; Hecht, JP; Mahmood, SM, 2019
)
1.71
"Intravenous (IV) hydralazine, enalapril and labetalol are oftentimes used without indication for the treatment of asymptomatic hypertension in the hospital setting and have been shown to have substantial adverse effects that are associated with increased morbidity and mortality, as well as longer length of stay."( Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.
Chams, N; Gjeka, R; Kumar, S; Peterson, D; Ross, I; Salman, A; Salman, J; Tegeltija, V, 2019
)
0.78
" Full-text, English-language articles describing IV labetalol and/or hydralazine use for non-emergent HTN in an inpatient setting that focused on clinical outcomes (ie vitals, adverse effects, healthcare utilisation) were included."( Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021
)
1.12
" The included studies presented a variety of outcomes, but several trends were identified, including reduction in average blood pressure in eight (80%) studies, a risk of adverse effects in six (60%) and increased length of stay in one (10%)."( Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Cawoski, JR; Covvey, JR; DeBiasio, KA; Donnachie, SW; Guarascio, AJ; Montepara, CA; Nemecek, BD; Timanus, EA; Zimmerman, DE, 2021
)
0.87
" Previous reports have demonstrated the adverse events during clinical application of LHCl, such as liver injury and acute renal failure."( Metabolic Activation and Cytotoxicity of Labetalol Hydrochloride Mediated by Sulfotransferases.
Hu, Z; Li, W; Peng, Y; Shi, J; Tian, M; Xin, L; Yang, L; Zheng, J, 2021
)
0.89
" Labetalol was safe and associated with higher neurological recovery."( Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children.
Angurana, SK; Bansal, A; Baranwal, A; Jayashree, M; Lad, S; Nallasamy, K; Patil, M, 2022
)
1.91
" Previous evidence suggests that management with one-time doses of intravenous (IV) antihypertensives may increase adverse events."( Reduction of Intravenous Antihypertensives through Clinical Decision Support in a Large Safety Net System.
Alaiev, D; Chandra, K; Cho, HJ; Garcia, M; Krouss, M; Manchego, PA; Shin, D; Talledo, J; Tsega, S; Zaurova, M,
)
0.13
" Safety was assessed according to adverse events that occurred during labetalol administration."( Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgical patients.
Duangprasert, G; Durongkaweroj, P; Noiphithak, R; Sukhor, S; Yindeedej, V, 2023
)
1.4

Pharmacokinetics

No significant differences were observed in the time to maximum concentration (tmax) or the distribution half-life (t1/2 alpha) between dilevalol and labetalol. Food did not alter the plasma half- life of labetAlol after oral or intravenous dosing.

ExcerptReferenceRelevance
" Correspondingly, the elimination half-life of dilevalol at steady-state is around 15h compared with 8h for labetalol."( Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly, R; Macphee, GJ, 1991
)
0.72
" This first evidence of labetalol stereoselective disposition is consistent with the findings of previous (R,R)-labetalol pharmacokinetic studies and with previous pharmacodynamic investigations of labetalol and (R,R)-labetalol."( Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition.
Bottorff, MB; Drda, KD; Herring, VL; Lalonde, RL; O'Rear, TL; Wainer, IW, 1990
)
2.03
" A possible pharmacodynamic interaction between oxazepam and the beta-adrenoceptor antagonists was examined using a simple reaction time test (SRT) and by measurement of postural sway."( Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol.
Døssing, M; Hamberg, O; Loft, S; Olesen, KL; Sonne, J; Thyssen, H; Victor, MA; Vollmer-Larsen, A, 1990
)
0.49
" No changes in any pharmacokinetic values for labetalol were detected as a function of age."( Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses.
Cressman, MD; Plachetka, JR; Rocci, ML; Sirgo, MA; Vlasses, PH, 1990
)
0.8
" Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function."( The pharmacokinetics of dilevalol in renal impairment.
Donohue, J; Doyle, GD; Kelly, JG; Laher, MS, 1990
)
0.28
" Blood samples for plasma dilevalol concentrations were taken during an 8-hour post-drug period following the first and eighth dosages, and the time to maximum concentration (tmax), maximum plasma concentration (Cmax), distribution half-life (t1/2 alpha), elimination half-life (t1/2 beta) and area under the plasma concentration-time curve (AUC) were determined."( Clinical pharmacology of dilevalol (III). A pharmacokinetic study of dilevalol in elderly subjects with essential hypertension.
Ebihara, A; Fujimura, A; Kumagai, Y; Nakashima, H; Sugimoto, K, 1989
)
0.28
"1 L/kg), and terminal half-life (11."( Pharmacokinetics and pharmacodynamics of dilevalol.
Affrime, MB; Bottorff, MB; Given, BD; Kramer, WG; Lalonde, RL; Patrick, JE; Tenero, DM, 1989
)
0.28
" No significant differences were observed in the time to maximum concentration (tmax), the distribution half-life (t1/2 alpha) or the elimination half-life (t1/2 beta) between dilevalol and labetalol."( Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
Ebihara, A; Fujimura, A; Kondo, K; Ohashi, K; Tsuru, M, 1989
)
0.67
" Studies of dilevalol's pharmacokinetics in normotensive and hypertensive volunteers have demonstrated that (1) it is rapidly and well absorbed; (2) because of extensive first-pass metabolism its absolute oral bioavailability is about 12%; (3) its mean elimination half-life is 8 to 12 hours after administration of single oral or intravenous doses to normal volunteers, a value consistent with once-daily dosing; and (4) food does not appear to alter its bioavailability or pharmacokinetics."( Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
Affrime, MB; Kramer, WG; Patrick, JE; Perentesis, G, 1989
)
0.28
" No significant differences were observed in the maximum plasma concentration (Cmax), the distribution half-life (t 1/2 alpha) or the elimination half-life (t 1/2 beta) between the two dosages."( Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjects.
Ebihara, A; Fujimura, A; Kondo, K; Ohashi, K; Tsuru, M, 1989
)
0.28
" Pharmacokinetic parameters for each subject after each study phase were estimated."( Interindividual and intraindividual variability in labetalol pharmacokinetics.
Awni, WM; Matzke, GR; Plachetka, JR; Schwenk, MH; Sirgo, MA; Skaar, DJ, 1988
)
0.53
" The assay has been used for the analysis of clinical samples in support of pharmacokinetic studies."( Combined use of an automated sample processor and a polymer-based high-performance liquid chromatographic column to determine the pharmacokinetics of labetalol in man.
Bates, J; Carey, PF; Godward, RE, 1987
)
0.47
" The steady-state plasma drug concentrations are predictable from the pharmacokinetic data and are in good agreement with the observed values."( Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients.
Chung, M; Gural, RP; Leitz, FH; Maier, G; Patrick, JE; Symchowicz, S, 1986
)
0.54
" For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15."( Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.
Elliott, HL; Meredith, PA; Reid, JL; Sumner, DJ, 1984
)
0.48
" The pharmacokinetic data best fit a two-compartment pharmacokinetic model with first order absorption."( Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol.
Barr, JW; Chung, M; Maronde, RF; Medakovic, M; Robinson, D; Vlachakis, ND; Zampaglione, N, 1983
)
0.48
" Most of the presently available pharmacokinetic information concerning labetalol is from studies utilising a fluorimetric assay but this has recently been superseded by more specific high-pressure liquid chromatographic (HPLC) procedures."( Clinical pharmacokinetics of labetalol.
Louis, WJ; McNeil, JJ,
)
0.65
"1 During chronic treatment of hypertensive patients observed mean steady-state plasma labetalol levels in ten patients were consistently and significantly higher than predicted from initial acute pharmacokinetic analysis."( Labetalol steady-state pharmacokinetics in hypertensive patients.
Anderson, AE; Louis, WJ; McNeil, JJ; Raymond, K, 1982
)
1.93
" Food did not alter the plasma half-life of labetalol after oral or intravenous dosing."( The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol.
Daneshmend, TK; Roberts, CJ, 1982
)
0.74
" Carvedilol and labetalol are the best known examples of such combined alpha/beta-adrenoceptor antagonists, although their pharmacodynamic profile is a result of different receptor selectivity of their component stereoisomers, rather than combined alpha/beta-blocking activity in a single chemical entity."( An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
van Zwieten, PA, 1993
)
0.63
" A pharmacokinetic study was therefore conducted to characterize the disposition of cocaine and a major metabolite benzoylecgonine (BE) using piglets as an animal model."( Effects of labetalol on cocaine pharmacokinetics in neonatal piglets.
Badger, TM; Burge, LJ; Creer, MH; Karba, R; Nehus, C; Primozic, S; Scalzo, FM, 1993
)
0.68
" Pharmacokinetic analysis shows the apparent elimination half-life of the metabolite to be 13."( Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep.
Abbott, FS; Axelson, JE; Doroudian, A; Hall, C; Kwan, E; Rurak, DW; Yeleswaram, K,
)
0.39
" The pharmacodynamic parameters (Emax and EC50) analyzed by the Emax model revealed a 3- to 5-fold interindividual variability."( Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993
)
1.73
"The renal and biliary excretion of the beta-adrenoceptor blocking agent dilevalol (CAS 75659-07-3) and its conjugates was examined in a preliminary pharmacokinetic study."( Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.
Becker, C; Henke, D; Mutschler, E; Neubeck, M; Rösch, W; Spahn-Langguth, H, 1993
)
0.29
"The pharmacokinetic data for the three drugs were qualitatively similar."( Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997
)
0.3
" Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects."( Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S, 1998
)
0.3
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"In two separate trials, we studied the concomitant administration of atosiban with labetalol and betamethasone to determine any possibility of a clinically relevant pharmacokinetic interaction."( Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Larsen, LS; Rasmussen, BB; Senderovitz, T, 2005
)
0.8
" Study 2 was an open-label, randomised, three-period crossover pharmacokinetic study."( Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Larsen, LS; Rasmussen, BB; Senderovitz, T, 2005
)
0.58
" Pharmacokinetic parameters (AUC, C(max), t(max)) did not differ markedly between treatments and all 90% CIs for ratios between treatments were fully within limits (80-125%)."( Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Larsen, LS; Rasmussen, BB; Senderovitz, T, 2005
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" In the present investigation, a method for the analysis of labetalol stereoisomers in human plasma was developed and applied to pharmacokinetic studies."( Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics.
Baraldi, Cde O; Carvalho, TM; Cavalli, Rde C; Da Cunha, SP; Lanchote, VL; Marques, MP, 2009
)
0.89
" Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model."( Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011
)
0.37
" Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
" Hepatic pharmacokinetic analysis showed that both the CL int and PS were significantly decreased in the RHF rat livers."( Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012
)
0.38
"Subjects with the CYP2C19 2/ 2 genotype had a higher peak concentration (255."( CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.
Chan, SW; Chow, MS; Fok, BS; Hu, M; Ko, SS; Tam, CW; Tomlinson, B; Yin, OQ, 2013
)
0.65
" Future larger studies are needed to evaluate the effect of CYP2C19 and UGT1A1 polymorphisms on the PK of labetalol stereoisomers and the pharmacodynamic effects."( CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.
Chan, SW; Chow, MS; Fok, BS; Hu, M; Ko, SS; Tam, CW; Tomlinson, B; Yin, OQ, 2013
)
0.87
" Estimation of population pharmacokinetic parameters and covariate effects was performed by nonlinear mixed effects modeling using NONMEM."( Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014
)
0.63
"A series of small pharmacokinetic studies illustrate higher oral clearance of labetalol and nifedipine during pregnancy."( The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021
)
0.85

Compound-Compound Interactions

Magnesium sulfate combined with nifedipine and labetalol has good efficacy in the treatment of preeclampsia. The study was a comparison of the effects on respiratory function produced by four antihypertensive agents.

ExcerptReferenceRelevance
"The study was a comparison of the effects on respiratory function produced by four antihypertensive agents with receptor-blocking properties (atenolol, oxprenolol, labetalol, metoprolol), when used in combination with a diuretic (chlorthalidone) in four homogeneous groups of hypertensive patients also suffering from chronic obstructive lung disease."( Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986
)
0.47
"To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia."( Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020
)
1.02
" Among them, 51 patients in the control group were treated with magnesium sulfate combined with nifedipine, and 49 patients in the experimental group were treated with labetalol on the basis of the treatment in the control group."( Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020
)
0.99
"Magnesium sulfate combined with nifedipine and labetalol has good efficacy in the treatment of preeclampsia."( Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020
)
1.06
"The aim of this study was to explore the hemodynamic changes of magnesium sulfate combined with labetalol in the treatment of pregnancy-induced hypertension (PIH) under Doppler uterine ultrasound based on the empirical wavelet transform (EWT) algorithm."( Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm.
Liu, C; Wang, F; Yin, X, 2022
)
1.17
" As a control, nifedipine combined with magnesium sulfate was administered."( Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension.
Gu, S; Shao, Y; Zhang, X, 2022
)
1.02
"Nifedipine, in combination with magnesium sulfate and labetalol, is effective at treating PIH, reducing blood pressure, improving blood coagulation, preventing cardiovascular events and vascular endothelial function, and further improve the pregnancy outcome."( Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension.
Gu, S; Shao, Y; Zhang, X, 2022
)
1.27

Bioavailability

Food caused a 38% increase in the mean systemic bioavailability of labetalol. There was a significant increase with age in both bioavailability and half-life. Co-administration of atosiban with betamethasone had no clinically relevant influence on their bioavailability or tolerability.

ExcerptReferenceRelevance
" Thus the bioavailability of labetalol was increased in liver disease due to reduced first-pass metabolism."( Decreased first-pass metabolism of labetalol in chronic liver disease.
Homeida, M; Jackson, L; Roberts, CJ, 1978
)
0.83
" From measurements of the total plasma radioactivity it was shown that labetalol was well absorbed by all the species."( Metabolism of labetalol by animals and man.
Bland, R; Hopkins, R; Martin, LE, 1976
)
0.85
"Twelve healthy male subjects completed this randomized, placebo controlled, four-period crossover trial to determine the effect of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine."( Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Danis, M; Dukes, GE; Hak, LJ; Han, YH; Hermann, DJ; Hussey, EK; Krol, TF; Powell, JR, 1992
)
0.75
" Both drugs are rapidly and completely absorbed in 60 to 90 min and subject to extensive first-pass hepatic metabolism; the average bioavailability after oral administration is around 20 to 35%, and there is wide interindividual variability in plasma drug concentrations and dosage requirements."( Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly, R; Macphee, GJ, 1991
)
0.51
" Carvedilol was absorbed rapidly after oral administration with a bioavailability of approximately 45% and obeyed linear pharmacokinetics over the dose range 25-50 mg."( A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Workman, BS, 1987
)
0.27
" Studies of dilevalol's pharmacokinetics in normotensive and hypertensive volunteers have demonstrated that (1) it is rapidly and well absorbed; (2) because of extensive first-pass metabolism its absolute oral bioavailability is about 12%; (3) its mean elimination half-life is 8 to 12 hours after administration of single oral or intravenous doses to normal volunteers, a value consistent with once-daily dosing; and (4) food does not appear to alter its bioavailability or pharmacokinetics."( Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
Affrime, MB; Kramer, WG; Patrick, JE; Perentesis, G, 1989
)
0.28
"The bioavailability and pharmacokinetics of dilevalol following oral and intravenous administration were investigated in 12 healthy male volunteers."( Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
Affrime, MB; Kramer, WG; Nagabhushan, N; Patrick, JE; Perentesis, GP; Symchowicz, S, 1988
)
0.27
" Labetalol is readily absorbed in man after oral administration, but the drug, which is lipid soluble, undergoes considerable hepatic first-pass metabolism and has an absolute bioavailability of approximately 25%."( Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
Bloomfield, SS; MacCarthy, EP,
)
2.48
" The bioavailability varies from 10% to over 80% in different subjects."( Clinical pharmacokinetics of labetalol.
Louis, WJ; McNeil, JJ,
)
0.42
"05), and systemic bioavailability was reduced from 30."( The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics.
Daneshmend, TK; Roberts, CJ, 1984
)
0.51
" The oral bioavailability ranged from 4 to 23%."( Single-dose pharmacokinetics of labetalol in healthy young men.
Hansson, R; Nyberg, G; Tietz, F, 1982
)
0.55
" There was a significant increase with age in both bioavailability and half-life of labetalol."( Bioavailability of labetalol increases with age.
Kelly, JG; McGarry, K; O'Brien, ET; O'Malley, K, 1982
)
0.82
" The oral bioavailability was calculated to be 16%."( Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.
Becker, C; Henke, D; Mutschler, E; Neubeck, M; Rösch, W; Spahn-Langguth, H, 1993
)
0.29
" It was a prerequisite to establish the bioavailability of oxazepam prior to succeeding studies on the oral disposition of the drug."( Factors and conditions affecting the glucuronidation of oxazepam.
Sonne, J, 1993
)
0.29
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The release characteristics of oral controlled-release medications are destroyed when crushed, resulting in the rapid bioavailability of the total drug amount."( Fatality from administration of labetalol and crushed extended-release nifedipine.
Hoffman, RS; Howland, MA; Nelson, LS; Schier, JG, 2003
)
0.6
"Labetalol had no clinically relevant influence on the bioavailability (AUC) of atosiban."( Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Larsen, LS; Rasmussen, BB; Senderovitz, T, 2005
)
2.02
"The co-administration of atosiban with betamethasone or labetalol had no clinically relevant influence on their bioavailability or tolerability."( Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Larsen, LS; Rasmussen, BB; Senderovitz, T, 2005
)
0.82
"The above TTS holds promise for improved bioavailability and better management of hypertension on long term basis."( In vitro and in vivo assessment of matrix type transdermal therapeutic system of labetalol hydrochloride.
Mittal, A; Parmar, S; Singh, B, 2009
)
0.58
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

IV nicardipine was 16 times more potent than labetalol in beta-adrenergic receptor blockade and was effective in lowering blood pressure in acute trials on spontaneously hypertensive rats at a dosage of 15 mg/kg. In the presence of renal functional impairment, no modification of labetAlol dosage is required. Initial dosing with nicardIPine lowered acute diastolic BP than labETalol (least square mean difference (labetalol-nicardipines)=5.5%)

ExcerptRelevanceReference
"Isoprenaline dose-response curves plotting increases in heart rate before and after labetalol are suggestive of competitive antagonism at beta-adrenoceptor sites."( Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.
Prichard, BN; Richards, DA; Tuckman, J, 1976
)
0.72
" 2 When given to 12 hypertensive patients at an average daily dosage of 273 mg for 7 months statistically significant reductions (compared with pretreatment values) in recumbent and standing blood pressure were observed."( Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
Hänel, B; Hansson, L, 1976
)
1.7
"4 X 10(-6) M) produced parallel shifts to the right of the dose-response curves to noradrenaline and oxymetazoline in isolated strips of cat splenic capsule."( The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen.
Blakeley, AG; Summers, RJ, 1977
)
0.61
" Both timolol and acebutolol had a significant hypotensive effect at 24 hours and a low incidence of side effects, suggesting that further increases in dosage might be effective and well tolerated."( Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.
Wilcox, RG, 1978
)
0.26
" 4 Dosage varied; average 889 mg/d, range 75-3,200 mg."( Labetalol in long-term treatment of hypertension.
Boakes, AJ; Prichard, BN, 1976
)
1.7
" The maximum exercise heart rate fell significantly during labetalol treatment, and there was a significant correlation between exercise tachycardia and the dosage of labetalol."( Effects of labetalol on plasma renin, aldosterone, and catecholamines in hypertensive patients.
Amery, AK; De Schaepdryver, AF; Fagard, RH; Lijnen, PJ; Moerman, EJ; Reybrouck, TM,
)
0.76
" We have studied the variations brought about by effective hypotensive therapy with an alpha and beta blocking agent (Labetalol) in 15 patients over a period of 90 days, with an average dosage of 420 mg/day in three divided doses."( [Systolic time intervals in essential hypertension. II. Variations produced by treatment with labetalol].
Lomanto, B; Rossi, A; Ziacchi, V, 1979
)
0.69
"1 Labetalol was given to 41 hypertensive patients in a divided dosage of 150--2,400 mg daily for periods ranging from 1--64 months."( Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.
Hussein, MM; Joekes, AM; Thompson, FD, 1979
)
1.32
" Oral dosage requirements of labetalol and possibly other drugs susceptible to first-pass metabolism are reduced in the presence of liver disease."( Decreased first-pass metabolism of labetalol in chronic liver disease.
Homeida, M; Jackson, L; Roberts, CJ, 1978
)
0.83
" It was not possible to saturate the melanin of the cat and dog eye even with prolonged dosing with labetalol."( Affinity of labetalol for ocular melanin.
Cook, J; Harrison, C; Martin, LE; Poynter, D, 1976
)
0.85
" Carvedilol shifts the dose-response curve to isoprenaline to the right, as well as to alpha-stimulants such as phenylephrine."( Clinical pharmacology of carvedilol.
Graham, BR; Prichard, BN; Tomlinson, B; Walden, RJ, 1992
)
0.28
"The dosage of urinary catecholamines and their metabolites is a main element of diagnosis in the research of a pheochromocytoma in patients with high blood pressure."( [Absence of labetalol interference on urine metanephrine determination in hypertensive patients].
Billaud, EM; Girerd, X; Laurent, S; Ropers, J; Safar, M; Safavian, A; Sorrel-Dejerine, A, 1992
)
0.66
" At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure."( Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991
)
0.52
" Further studies are indicated to determine appropriate dosing regimens for oral labetalol in the acute treatment of severe hypertension."( Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension.
Atkin, SH; Beaty, P; Cuffie, C; Jaker, MA; Quadrel, MA; Soto-Greene, ML, 1992
)
1.02
" For the labetalol group, the dosage was titrated from 400 mg to 600 mg per day to achieve a fall of 10 mmHg in mean arterial pressure (MAP)."( Lack of effect of labetalol on platelet aggregation in hypertensive patients.
Huang, CS; Lin, MS, 1991
)
1.03
" Once blood pressure control (standing diastolic blood pressure [SDBP] less than 90 mm Hg and greater than or equal to 10 mm Hg reduction from baseline) was achieved or the maximum allowable dosage had been given, the dosage remained the same until the end of the study."( Evaluation of labetalol in elderly patients with essential hypertension.
Bartels, DW; Burris, JF; Due, D; Giles, TD; Gregory, MC; Sirgo, MA; Weber, M, 1991
)
0.64
" Both drugs are rapidly and completely absorbed in 60 to 90 min and subject to extensive first-pass hepatic metabolism; the average bioavailability after oral administration is around 20 to 35%, and there is wide interindividual variability in plasma drug concentrations and dosage requirements."( Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly, R; Macphee, GJ, 1991
)
0.51
" Dosage titration occurred at weekly intervals for labetalol and biweekly for atenolol."( Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.
DiPette, DJ; Goodman, RP; McKenney, JM; Townsend, R; Wright, JT, 1991
)
0.77
" Hemodynamic parameters, including supine and standing DBP, systolic blood pressure (SBP), and heart rate (HR), were measured and safety was evaluated at baseline and at days 14, 28, and 56 at the end of the dosing interval."( Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP, 1990
)
0.52
" N-1518 blocked alpha- and beta-adrenoceptors competitively as indicated by parallel rightward displacement of the dose-response curve of each agonist in isolated organs and in anesthetized dogs."( [Pharmacological properties of (+/-)-4-[2-hydroxy-3-(3-(2-methoxyphenoxy)-2-propylamino)propoxy]-1(2H) -isoquinolinone (N-1518), a new combined alpha- and beta-adrenoceptor blocking drug].
Sugai, T, 1990
)
0.28
" The patients' BP and heart rate were evaluated biweekly by trained observers unaware of the treatment status, and drug dosage was titrated (up to 400 mg twice a day of labetalol or 40 mg daily of enalapril) to achieve a standing diastolic BP of less than 90 mm Hg and a decrease of 10 mm Hg from baseline."( Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring.
Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA, 1991
)
0.84
" It is available in a tablet dosage form, which may be difficult to administer to geriatric and pediatric patients."( Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices.
Nahata, MC, 1991
)
0.65
" Although 28 patients required no further labetalol in the maintenance period, in the others dosage varied from 5 to 400 mg."( Labetalol for the control of elevated blood pressure following coronary artery bypass grafting.
Goldberg, JS; Klamerus, KJ; Leslie, JB; Levitsky, S; Mann, HJ; Mills, SA; Molina, JE; Prough, DS; Sladen, RN; Swafford, MW, 1990
)
1.99
" The recommended dosage range of dilevalol, of 200-400 mg once-daily, has generally been shown to be at least as effective at lowering raised blood pressure as established antihypertensive agents given according to their recommended doses."( Overview of clinical trials of dilevalol in essential hypertension.
Glover, DR; Tarbit, WJ, 1990
)
0.28
" Once the BP was controlled (standing systolic BP less than 160 mm Hg, and greater than or equal to 10-mm Hg decrease from baseline) or the maximum dosage had been given, patients continued receiving the same regimen until the end of the titration period and throughout a 4-week maintenance period."( Treatment of isolated systolic hypertension with labetalol in the elderly.
Bartels, DW; Burris, JF; Gilderman, LP; Giles, TD; Silberman, HM; Weber, M, 1990
)
0.53
"This randomized multicentre study in elderly hypertensives with two unbalanced groups (2 patients under labetalol for 1 patient under nifedipine) compared the efficacy and safety of labetalol, whose dosage could be adjusted (1, 2, then 3 tablets/day) according to blood pressure level (BP greater than or equal to 160/95 mmHg), to that of nifedipine given at its recommended dosage (2 tablets/day)."( [Hypertension in the elderly. Comparison of the efficacy and tolerability of labetalol and nifedipine. A multicenter, randomized, single-blind study].
d'Allens, H; Decoulx, M; Godon, P; Pappo, M, 1990
)
0.72
" Blood pressure and heart rate were measured at rest and during bicycle exercise tests 4 ("peak") and 24 hours ("trough") after dosing in the dilevalol group and 4 ("peak") and 12 hours ("trough") after dosing in the captopril group."( Antihypertensive activity and duration of action of dilevalol in hypertensive patients at rest and during exercise. A comparison with captopril.
Cesana, B; Fogari, R; Poletti, L; Savonitto, S; Tettamanti, F, 1990
)
0.28
" A randomized, double-blind, placebo-controlled, cross-over trial with two 4 week treatment periods was used to compare the efficacy of once daily dosing with dilevalol (in the range of 100-400 mg daily) against placebo."( A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring.
Farish, S; McGrath, BP; McNeil, JJ; Silagy, CA, 1990
)
0.28
" The patients' blood pressure and heart rate were evaluated biweekly and drug dosage was titrated (up to 400 mg and 50 mg bid of labetalol and HCTZ, respectively) to achieve a standing diastolic blood pressure less than 90 mm Hg."( Comparison of labetalol and hydrochlorothiazide in elderly patients with hypertension using 24-hour ambulatory blood pressure monitoring.
Due, DL; Sirgo, MA; Toth, PD; Vidt, DG; Weidler, DJ, 1990
)
0.84
" The beta-antagonist effects of the three substances were also studied, by running a dose-response curve to noradrenaline or adrenaline as appropriate following the addition of the substance of interest."( Effects of dilevalol on human atrial muscle.
Brown, MJ; Sanders, L, 1990
)
0.28
"In pithed rats two recently-introduced beta-blockers, nipradilol and arotinolol, as well as labetalol shifted the pressor dose-response curve for phenylephrine to the right."( Alpha-blockade and vasodilatation induced by nipradilol, arotinolol and labetalol in pithed rats.
Chin, WP; Imai, S; Nakagawa, Y; Nakahara, H, 1985
)
0.72
" The dose-response curve for this action is comparable to that of propranolol."( Cellular electrophysiology and beta-adrenergic-blocking activity of dilevalol, the R,R-isomer of labetalol, on isolated canine cardiac tissues.
Dangman, KH; Zaim, S, 1989
)
0.49
" Doses were calculated to produce plasma levels approximating those achieved after oral dosing (0."( Effects of dilevalol on forearm circulation in essential hypertension.
Cleroux, J; Giannattasio, C; Grassi, G; Mancia, G; Seravalle, G; Zanchetti, A, 1989
)
0.28
" This was followed by a 2-week once-a-day dosing regimen in which patients received the same total daily dose as the prior 2 weeks, with the full dose in the morning and a matched placebo in the evening."( The efficacy and safety of dilevalol in patients with chronic stable angina pectoris.
Bennett, WT; Bittar, N; Glasser, SP; Kinhal, V; Koehn, DK, 1989
)
0.28
" In both study populations renal function tests commenced two hours after dosing at expected peak plasma levels of dilevalol."( The renal function and blood pressure effects of dilevalol in the normotensive and hypertensive elderly.
Clifton, GG; Cook, ME; Poland, M; Wallin, JD, 1989
)
0.28
" The mean time to maximum concentration (tmax) was faster, and the mean area under the plasma concentration-time curve (AUC) was greater after 15th dosage than following 1st dosage."( Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjects.
Ebihara, A; Fujimura, A; Kondo, K; Ohashi, K; Tsuru, M, 1989
)
0.28
"Severe hypertension may be a difficult management issue, and it often requires therapy with multiple drugs at frequent dosing intervals."( Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
Aydelotte, ME; White, WB, 1988
)
0.58
" Propranolol and labetalol induced a dose-dependent, parallel shift to the right in the dose-response curves of isoproterenol effects on heart rate and diastolic blood pressure, indicating that both drugs are nonselective, competitive antagonists of beta-adrenergic receptors."( Beta blockade by oral propranolol and labetalol.
Carr, ME; Cubeddu, LX; Fuenmayor, NJ, 1985
)
0.88
" Labetalol 400 mg significantly shifted the blood pressure dose-response curve to the right."( Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man.
Harron, DW; Riddell, JG; Shanks, RG, 1985
)
1.46
" The dose-response curves of dilevalol and labetalol were shifted to the right with propranolol pretreatment."( Intrinsic beta-sympathomimetic activity of dilevalol, R, R-isomer of labetalol.
Matsunaga, K; Nakamura, K; Ueda, M, 1985
)
0.77
" Experiments carried out in vitro showed that labetalol relaxed the tonus of isolated tracheal preparation, shifting the histamine dose-response curve to the right and downward."( [A study on the mechanism of the antiasthmatic effect of labetalol on experimental histamine-induced asthma].
Kameda, H; Monma, Y; Tanabe, T, 1986
)
0.77
" The usual dosage in patients without hypertension is 200 mg twice daily, but in patients with hypertension doses up to 1200 mg or even more have been used."( Labetalol in the treatment of angina pectoris.
Kanto, JH, 1987
)
1.72
" Labetalol and prazosin also significantly shifted the dose-response curve to the right for phenylephrine but not for angiotensin II."( Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.
Akashi, A; Hashimoto, H; Kanda, A; Tanaka, M, 1988
)
1.19
" Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared."( Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.
Bompart, F; Graham, BR; Liu, JB; Prichard, BN; Tomlinson, B, 1988
)
0.49
"02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645."( [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988
)
0.48
" Labetalol therapy was then initiated at 100 mg twice a day in a single-blind manner and increased weekly by 100 mg twice a day until blood pressure control was obtained or a maximum dosage of 400 mg twice a day was reached."( Labetalol blunts morning pressor surge in systolic hypertension.
Allen, J; DeQuattro, V; Lee, DD; Plachetka, J; Sirgo, M, 1988
)
2.63
" The duration of action also varied in the labetalol group, with the shortest duration occurring in those patients who required the highest dosage for BP control."( A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.
Amon, E; Gonzalez, AR; Mabie, WC; Sibai, BM, 1987
)
0.85
" With the dosage regimen used in this study there was a tendency towards more effective blood pressure control with dihydrallazine."( Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy.
Ashe, RG; Moodley, J; Philpott, RH; Richards, AM, 1987
)
0.63
" Labetalol caused lowering of the blood pressure and heart rate during the phase of intravenous treatment, but little effect occurred subsequently because oral dosage was constrained by low systolic pressures."( Effect of labetalol on indices of myocardial necrosis in patients with suspected acute infarction.
Burwood, RD; Chamberlain, DA; Haskett, VL; Heber, ME; Lutkin, J; Rosenthal, E; Thomas, N; Vincent, R, 1987
)
1.59
", following the initial dose of active treatment) and on each visit when the dosage was increased."( The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol.
Blasucci, DJ; Falliers, CJ; Maloy, JW; Medakovic, M; Vrchota, J, 1985
)
0.56
" Heart rate was lowest during propranolol dosing and blood pressure was lowest during labetalol dosing irrespective of the labetalol dose used."( Chronic effects of labetalol, pindolol, and propranolol on calf blood flow in intermittent claudication.
Lepäntalo, M, 1985
)
0.82
" Maximal symptom limited treadmill exercise tests were performed three and 12 hours after dosage at each dose."( Oral labetalol in the management of stable angina pectoris in normotensive patients.
Akhras, F; Jackson, G; Upward, JW, 1985
)
0.78
" Amniotic fluid concentrations 2-3 h after dosing were generally lower than in plasma."( Transfer of labetalol into amniotic fluid and breast milk in lactating women.
Kulas, J; Lunell, NO; Rane, A, 1985
)
0.65
"The effectiveness, safety, and pharmacodynamics of repeated doses of intravenous labetalol for rapid reduction of severe hypertension and of subsequent oral labetalol dosing were studied."( Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol.
Kassem, N; Maloy, JW; Maronde, RF; Medakovic, M; Vlachakis, ND, 1985
)
0.78
" The dosage and choice of drugs are based on pharmaco-kinetic and dynamic data in animals and man."( Clinical pharmacology of beta-adrenoceptor antagonism in angina pectoris: an overview.
Oh, VM, 1980
)
0.26
" 3a was 16 times more potent than labetalol in beta-adrenergic receptor blockade and was effective in lowering blood pressure in acute trials on spontaneously hypertensive rats at a dosage of 15 mg/kg."( 2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
Franke, A; Frickel, FF; Gries, J; Lenke, D; Schlecker, R; Thieme, PD, 1981
)
0.54
" The ratios of beta 1- to alpha 1-adrenoceptor antagonism as calculated from the relative shifts of the isoprenaline and phenylephrine dose-response curves, were 3 to 1 for labetalol and about 7 to 1 for medroxalol."( Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
Elliott, HL; McLean, K; Meredith, PA; Reid, JL; Sumner, DJ, 1984
)
0.75
" SCH 19927 produced a competitive alpha 1- and beta 1-blockade in vitro as indicated by the parallel shift to the right of the dose-response curves for norepinephrine and isoprenaline, respectively."( Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
Bamonte, F; Forlani, A; Monopoli, A; Ongini, E; Parravicini, L, 1984
)
0.56
" A dosage of 100mg twice daily will often be adequate to control mild hypertension and the use of even lower doses has been reported."( Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Prichard, BN, 1984
)
0.27
"(1) When incremental infusions of drugs that increase blood pressure are given to human subjects to assess "pressor responsiveness," only the lower part of the sigmoid dose-response curve can be obtained."( Analysis of the pressor dose response.
Elliott, HL; Reid, JL; Sumner, DJ, 1982
)
0.26
" 4 Efficacy of labetalol as a beta-adrenoceptor antagonist and anti-hypertensive drug was assessed 2 h after an oral dose during chronic eight hourly dosage in sixteen hypertensive patients."( Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.
Davies, DM; Rawlins, MD; Sanders, GL, 1980
)
0.84
" 2 Salbutamol airway dose-response curves were obtained by measuring the airway response as the change in specific airway conductance (sGaw) after increasing doses of inhaled salbutamol."( Bronchial and cardiac beta-adrenoceptor blockade--a comparison of atenolol, acebutolol and labetalol.
Baldwin, CJ; Gribbin, HR; Mackay, AD; Tattersfield, AE, 1981
)
0.48
" Norepinephrine ED50 values and dissociation constants (KA) were determined by analysis of dose-response data with and without partial inactivation of alpha receptors by phenoxybenzamine."( Qualitative and quantitative differences between the postsynaptic alpha adrenoceptors of rabbit ear artery and thoracic aorta.
Ashbrook, DW; Purdy, RE; Stupecky, GL; Watanabe, MY, 1983
)
0.27
"To test the hypothesis that the depression of cardiac performance induced by competitive blockade of sympathetic stimulation at beta-adrenoceptors could be attenuated by the addition of a high level of intrinsic sympathomimetic activity (ISA) or concomitant alpha- and beta-blockade, the haemodynamic dose-response effects of propranolol (non-cardioselective, no ISA), pindolol (non-cardioselective, high ISA) and labetalol (non-cardioselective, alpha-blocker) were compared in a randomized study of 30 patients with stable coronary artery disease."( Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile.
Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH, 1983
)
0.43
" Although DbH did not change, plasma concentrations of norepinephrine (NE) and its major metabolites and of OTP increased between 2 and 4 hr after dosing and remained elevated up to 12 hr."( Acute effect of labetalol on blood pressure in relation to the sympathetic nervous system and plasma renin activity.
Alexander, N; Barr, J; Maronde, R; Velasquez, M; Vlachakis, ND, 1984
)
0.61
" The average daily dosage was 144."( Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol.
Blazquez, G; Chouty, F; Flouvat, B; Gerard, J; Lardoux, H, 1983
)
0.5
"The comparative haemodynamic dose-response effects of beta- (propranolol) or alpha- plus beta-blockade (labetalol) were evaluated in a randomised between-group study of 16 patients with an uncomplicated acute myocardial infarction."( Comparison of haemodynamic dose-response effects of beta- and alpha-beta-blockade in acute myocardial infarction.
Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH; Walker, C, 1984
)
0.48
" Wide variation in dosage was needed both from case to case and in the same patient during the course of his disease."( Labetalol in tetanus. The treatment of sympathetic nervous system overactivity.
Hariparsad, D; Pather, M; Rocke, DA; Wesley, AG, 1983
)
1.71
" The dosage was first titrated out and assessed in a double-blind cross-over trial."( Treatment of hypertension in the elderly with labetalol.
Eisalo, A; Virta, P, 1982
)
0.52
" With a mean dosage of 15 mg, labetalol reduced both systemic arterial pressures and the heart rate by an average of 21 percent (p < ."( Combined alpha- and beta-blockade with labetalol in post-open heart surgery hypertension. Reversal of hemodynamic deterioration with glucagon.
Allonen, H; Arola, M; Laaksonen, VO; Meretoja, OA, 1980
)
0.82
" After an initial period of dosage adjustment and a 2 months treatment in effective doses, there was a significant fall in supine blood pressure from mean values of 207/132 to 170/106 mmHg."( [Effects of labetalol, a new alpha- and beta-adrenoreceptor blocking drug, on arterial pressure, renal function and renin activity (author's transl)].
Pozet, N; Sassard, J; Vincent, M; Zech, P, 1980
)
0.64
" Side effects necessitated stopping the drug at less than adequate dosage in some patients who might also have proved resistant to labetalol and other drugs were added to improve blood pressure control in 25 patients who continued labetalol."( A multicentre study of labetalol in hypertension. New Zealand Hypertension Study Group.
, 1981
)
0.78
" Patients were started on either 100 mg labetalol or 250 mg alpha-methyldopa 3-times daily and, if necessary, the dosage adjusted by standard increments every 2 weeks over a period of a month until satisfactory control was achieved."( A controlled comparison of the antihypertensive effects of labetalol and alpha-methyldopa.
Al-Damluji, SF; Al-Khalidi, A; Shaarbaf, H; Tawfiq, NH, 1982
)
0.78
" 5 In the presence of renal functional impairment, no modification of labetalol dosage is required."( Elimination kinetics of labetalol in severe renal failure.
Bailey, RR; Ferry, DG; Wood, AJ, 1982
)
0.81
"One hundred and fifty-seven hypertensive patients (1st and 2nd degree of the WHO classification) studied in 15 hospitals were treated with labetalol at a dosage of 300-600 mg a day for 3 months."( [Treatment of arterial hypertension with labetalol. A polycentric study].
, 1982
)
0.73
" In all the drug-treated groups, increase in salivation was observed from immediately to 15 minutes after dosing through the treatment period."( [On the subacute toxicity of labetalol (AH5158): a combined alpha-and beta-adrenoceptor blocking agent (author's transl)].
Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1980
)
0.55
" The dosage was individualized on the basis of hypotensive response and side effects until an acceptable blood pressure was achieved."( Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy.
Rossi, AG, 1981
)
0.56
" In all the drug-treated groups, increase in salivation was observed from immediately after to 15 minutes after dosing through treatment period."( [On the chronic toxicity of labetalol (AH-5158); a combined alpha-and beta-adrenoceptor-blocking agent (author's transl)].
Fujiwara, S; Shimpo, K; Tanabe, T; Togashi, H; Yokoi, Y, 1981
)
0.56
" After a 2 to 4-week period on placebo, patients received 200 mg labetalol daily for 4 weeks, after which time dosage was doubled if the blood pressure was not satisfactorily controlled."( Experience with labetalol in essential hypertension.
Elo, J; Nissinen, A; Tuomilehto, J, 1980
)
0.84
" Initial dosage was 300 mg per day."( Labetalol ('trandate') in hypertension: a multicentre study in general practice.
Gomez, G; Phillips, LA, 1980
)
1.7
" The resting heart rate is faster with labetalol than with an equivalent dosage of propranolol."( Comparison of labetalol and propranolol in treatment of hypertension.
Harvald, B, 1980
)
0.89
" The current drug classes are reviewed with respect to dosage guidelines, adverse effects and potential drug-drug interactions."( Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.
Miller, K, 1994
)
0.29
" More controlled trials with less aggressive dosing regimens and placebo controls need to be performed to assess the most appropriate treatment for HUs with the fewest adverse effects."( Oral antihypertensives for hypertensive urgencies.
Gales, MA, 1994
)
0.29
" These dosages were individually selected by attaining a therapeutic goal of DBP < or = 100 mm Hg or systolic blood pressure (SBP)/DBP reduction of > 30/15 mm Hg, as compared with the pretreatment value, at any time during the 12-hour dosing interval for a 3- to 5-day dosage escalation period."( Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.
Echizen, H; Ishizaki, T; Minoura, S; Saotome, T; Sato, T; Terashi, K, 1993
)
1.73
" Labetalol was used as antihypertensive agent and was given in repeated bolus (up to total dose of 2 mg/kg) intravenously before skin incision and no supplemental dosage was given later on."( Preliminary experience of using fixed dose of intravenous labetalol in surgical resection of pheochromocytoma.
Chung, PC; Sum, DC, 1993
)
1.44
" The dose of isoprenaline required to increase heart rate by 25 beats min-1 (I25) and the dose of phenylephrine required to increase systolic and diastolic blood pressure by 20 mm Hg (PS20 and PD20) were calculated using a quadratic fit to individual dose-response curves."( The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
Guy, S; McDermott, BJ; Riddell, JG; Shanks, RG; Tham, TC, 1995
)
0.29
"The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1996
)
0.66
"001) at 1 hour after nifedipine dosing (99 +/- 99 mL) compared with labetalol (44."( A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999
)
0.77
" Hemodynamic parameters at dosing and at 15, 30, 60, and 120 minutes were recorded."( A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies.
Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999
)
0.54
" If mean arterial pressure (MAP) increased >80 mm Hg during maximal dosage of isoflurane or remifentanil, labetalol was administered."( Remifentanil provides hemodynamic stability and faster awakening time in transsphenoidal surgery.
Cozzi, S; Gemma, M; Losa, M; Mortini, P; Narcisi, S; Soldarini, A; Tommasino, C, 2002
)
0.53
" This report does not suggest the routine use of low-dose spinal anesthesia without supplements, but illustrates the wide variability in dosage and sensitivity to spinal anesthetics, and suggests that further research is needed in this area, particularly in morbidly obese parturients."( Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
Pan, PH; Reyes, M, 2004
)
0.32
" The number of patients with intraoperative hypertension or hypotension, dosage of SNP administered, number of intraoperative hypertension episodes, use of fluid and blood transfusion, and heart rate (defined as the mean of heart rate every 5 minutes throughout the operation) were compared between these two groups."( Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma.
Chung, PC; Hsieh, JR; Li, AH; Ng, YT; Yang, MW, 2006
)
1.78
" The objective of this study is to ascertain the mechanisms underlying its absorption as an approach to help in predicting the influence of dosage changes, possible drug-drug and drug-fruit juice interactions."( Labetalol absorption kinetics: rat small intestine and colon studies.
Abushammala, I; Casabó, VG; Garrigues, TM; Martín-Villodre, A; Nácher, A, 2006
)
1.78
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension."( CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.
Baumann, BM; Borczuk, P; Cannon, CM; Chandra, A; Cline, DM; Diercks, D; Hiestand, B; Hsu, A; Jois-Bilowich, P; Kaminski, B; Levy, P; Nowak, RM; Peacock, WF; Schrock, JW; Varon, J, 2011
)
0.8
"Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration."( Neonatal side effects of maternal labetalol treatment in severe preeclampsia.
Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012
)
0.92
"This is a substudy of the multicenter safety and efficacy Evaluation of intravenous Cardene (nicardipine) and Labetalol Use in the Emergency department (CLUE) trial that randomized patients to Food and Drug Administration-recommended intravenous dosing of nicardipine or labetalol to reach a physician predefined systolic BP (SBP) and target range (TR) of ±20 mm Hg within 30 minutes."( Impact of initial blood pressure on antihypertensive response in patients with acute hypertension.
Farias, S; Gonzalez, M; Levy, PD; Peacock, WF, 2014
)
0.61
"Adequate initial dosing of antihypertensive treatment has the potential to reduce time to blood pressure control and possibly time to alteplase therapy."( Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
Cortes, J; Hall, AB; McKay, C, 2015
)
0.63
" There was no statistical significant difference on dosage of drugs used or incidence ofside effect (hypotension, bradycardia, heart block, and bronchospasm)."( An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015
)
0.7
" Both drugs used low median dosage giving low incidence of side-effects."( An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Punkla, W; Raksamani, K; Rushatamukayanunt, P; Sakaew, A; Sirivanasandha, B; Sutthivaiyakit, K; Waitayawinyu, P, 2015
)
0.7
" Oral Nifedipine may be a better alternative because of its ease of oral administration and a flat dosing regimen."( IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial.
Sowjanya, R; Tatapudi, R; Zulfeen, M, 2019
)
1.14
" In this paper, pristine few layer graphene (FLG) was applied to interact with laccase to synthesize laccase-graphene composite and the results of AFM, FT-IR and adsorption isotherm suggested that laccase was loaded on the FLG with a very high loading dosage (221."( Non-covalent assembled laccase-graphene composite: Property, stability and performance in beta-blocker removal.
Cao, Y; Dong, S; Gao, S; Jing, X; Mao, L; Xia, E, 2019
)
0.51
" From the beginning of the pregnancy to the end of the puerperium, the low dosage aspirin group (n = 129), the labetalol group (n = 127), and the drug-free or control group (n = 126) reported both mother and child results."( Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020
)
1.01
" However, antihypertensive drugs lack pregnancy-specific dosing recommendations due to critical knowledge gaps surrounding the extent of gestational changes in antihypertensive drug pharmacokinetics and underlying mechanisms."( The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021
)
0.62
"This review (1) summarizes currently recommended medications and dosing strategies for non-emergent HDP treatment, (2) reviews and synthesizes existing literature identified via a comprehensive PubMed search evaluating gestational changes in the maternal pharmacokinetics of commonly prescribed HDP drugs (notably labetalol and nifedipine), and (3) offers insight into the metabolism and clearance mechanisms underlying altered HDP drug pharmacokinetics during pregnancy."( The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021
)
0.8
" Future research is needed to address various evidence gaps and inform the development of more precise antihypertensive drug dosing strategies."( The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021
)
0.62
"This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy."( Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials.
Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022
)
1.19
" Initial dosing with nicardipine lowered acute diastolic BP than labetalol (least square mean difference (labetalol-nicardipine)=5."( Initial antihypertensive agent effects on acute blood pressure after intracerebral haemorrhage.
Behymer, TP; Bettin, M; Christianson, T; Coleman, ER; Divani, A; Flaherty, ML; Gilkerson, LA; James, ML; King, NKK; Krishnamoorthy, V; Langefeld, CD; McCauley, JL; Ng, Y; Qi, W; Shah, S; Testai, FD; Walsh, KB; Woo, D, 2022
)
0.96
" Aiming for evidence-based and personalized dosing of antihypertensive medication in the future, further studies on the relationship of both PK and pharmacodynamics (including the optimal blood pressure targeting) during pregnancy and pregnancy-related pathology are urgently needed to prevent undertreatment, overtreatment, and side effects."( Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022
)
0.94
" However, there were big differences in dosage regimens between various guidelines."( Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023
)
1.14
"A physiologically-based pharmacokinetics (PBPK) model was established and validated to evaluate the existing oral dosage regimens, and to compare the difference in plasma concentration between pregnant and non-pregnant women."( Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023
)
1.14
" The following simulations with criteria lowering 15 mmHg blood pressure (corresponding to around 108 ng/ml plasma labetalol) found that the maximum daily dosage in the Chinese guideline may be insufficient for some severe HDP patients."( Physiologically Based Pharmacokinetic Modeling for Multiple Oral Administration Labetalol in Pregnant Women.
Chen, D; Chen, J; Li, W; Liu, X; Ouyang, D; Song, Y; Wang, W; Wang, X, 2023
)
1.35
" Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)."( Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia.
Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (7)

ClassDescription
benzamides
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
salicylamides
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Labetalol Action Pathway488

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.43050.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493107
Ataxin-2Homo sapiens (human)Potency17.78280.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)649.10000.11007.190310.0000AID1449628
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.01600.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.01100.00000.66359.5499AID625205
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)3.35400.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki3.32600.00322.28879.3160AID625207
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.01000.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.00580.00011.33919.9840AID625204
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.80000.00002.015110.0000AID625249
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.39300.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.22500.00010.739610.0000AID625190
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)3.35400.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki3.32600.00031.465610.0000AID625207
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.52100.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.25600.00000.360910.0000AID625200
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.39300.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.22500.00031.29679.2440AID625190
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)3.03700.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki1.93300.00030.769310.0000AID625217
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)1.60700.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki1.27700.00021.11158.0280AID625256
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)1.81500.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.76300.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd0.03160.00000.53588.3176AID40102
Beta-2 adrenergic receptorHomo sapiens (human)Kd0.23130.00000.62888.9130AID1798580
Beta-1 adrenergic receptorHomo sapiens (human)Kd0.23130.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd0.23130.00010.76318.9130AID1798580
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd10.00000.00020.62779.3325AID35487
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd10.00000.00020.62779.3325AID35487
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd10.00000.00020.62779.3325AID35487
Alpha-1D adrenergic receptorHomo sapiens (human)Kd0.15850.00000.19451.2882AID36428
Alpha-1A adrenergic receptorHomo sapiens (human)Kd0.15850.00000.20481.2882AID36428
Alpha-1B adrenergic receptorHomo sapiens (human)Kd0.15850.00000.11991.2882AID36428
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)Kd0.03980.00020.54774.4668AID41023
HeparanaseHomo sapiens (human)Kd1,000.00000.24000.24000.2400AID738328
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (193)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
proteoglycan metabolic processHeparanaseHomo sapiens (human)
cell-matrix adhesionHeparanaseHomo sapiens (human)
response to organic substanceHeparanaseHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHeparanaseHomo sapiens (human)
positive regulation of blood coagulationHeparanaseHomo sapiens (human)
heparan sulfate proteoglycan catabolic processHeparanaseHomo sapiens (human)
heparin metabolic processHeparanaseHomo sapiens (human)
positive regulation of osteoblast proliferationHeparanaseHomo sapiens (human)
regulation of hair follicle developmentHeparanaseHomo sapiens (human)
positive regulation of hair follicle developmentHeparanaseHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionHeparanaseHomo sapiens (human)
establishment of endothelial barrierHeparanaseHomo sapiens (human)
vascular wound healingHeparanaseHomo sapiens (human)
protein transmembrane transportHeparanaseHomo sapiens (human)
angiogenesis involved in wound healingHeparanaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
beta-glucuronidase activityHeparanaseHomo sapiens (human)
protein bindingHeparanaseHomo sapiens (human)
heparanase activityHeparanaseHomo sapiens (human)
syndecan bindingHeparanaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
extracellular regionHeparanaseHomo sapiens (human)
nucleusHeparanaseHomo sapiens (human)
nucleoplasmHeparanaseHomo sapiens (human)
lysosomeHeparanaseHomo sapiens (human)
lysosomal membraneHeparanaseHomo sapiens (human)
specific granule lumenHeparanaseHomo sapiens (human)
lysosomal lumenHeparanaseHomo sapiens (human)
intracellular membrane-bounded organelleHeparanaseHomo sapiens (human)
membrane raftHeparanaseHomo sapiens (human)
extracellular spaceHeparanaseHomo sapiens (human)
extracellular matrixHeparanaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (256)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID35487The compound was evaluated for the antagonistic activity against alpha-2 adrenergic receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID187313Potency (vasodilation) relative to labetolol1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1221002Permeability surface area product in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID587818Apparent permeability across human Caco2 cells2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID180104Maximal change in heart rate (HR) measured as pretreatment value at dose of 25 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668033Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID187452Relative potency required for inhibition of L-phenylephrine-induced pressor response in pithed rats1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID41023The compound was evaluated for the antagonistic activity against beta-2 adrenergic receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1220980Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID40418Potency to block Beta-1 adrenergic receptor relative to labetolol1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID173886Decrease in blood pressure(mm/Hg) was determined after administration of (10 mg/kg/po); 30-32/>41982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1221010Apparent distribution ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID171496Antihypertensive activity was determined before dosing in conscious, spontaneously hypertensive rats(SHR)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1220990Mean transit time of the compound in healthy Wistar rat perfused liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID171752Change in blood-pressure was determined after 4 hr administration of (10 mg/kg/po) in conscious, spontaneously hypertensive rats(SHR)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1305705Permeability across apical side at pH 6.5 to basolateral side at pH 7.4 in human Caco2 cells at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID732419Efflux ratio of permeability from basolateral to apical side over apical to basolateral in pig LLC-PK1 cells overexpressing human MDR12013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
AID26287Partition coefficient (logD3.0)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID187451Relative potency required for hypotensive activity in anesthetized rat1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1220994Mean transit time of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID173811Dose required for hypotensive activity in anesthetized rat after intravenous administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID40102The compound was evaluated for the antagonistic activity against beta-1 adrenergic receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID172563Maximal change in mean arterial blood pressure (MABP) measured as % change from pretreatment value at dose of 25 mg/kg1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID173809Dose required for antihypertensive activity in spontaneous hypertensive rats after oral administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID180459Antihypertensive activity was determined by Heart rate(beats/min) measurement before dosing in conscious, spontaneously hypertensive rats1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID186534Maximal change in mean arterial blood pressure (MABP) measured as pretreatment value at dose of 25 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID42044Beta-1 adrenergic receptor ISA (intrinsic sympathomimetic activity)using the guinea pig right atria was measured as % increase of positive chronotropic effect (basal spontaneous beating rate) at 1x10E-6 M1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1382491Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 60 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1382492Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 60 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID171748Change in blood-pressure was determined after 2 hr administration of (10 mg/kg/po) in conscious, spontaneously hypertensive rats(SHR)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1860216Apparent permeability of the compound from apical to basolateral side in human Caco-2 cells at pH 6.5 to 7.42022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
AID1305707Permeability across apical side at pH 6.5 to basolateral side at pH 7.4 in human Caco2 cells assessed as compound recovery at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID33141Potency(alpha block) relative to labetolol1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID230265Ratio of Relative potency of beta1/alpha bock values; 29-391982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1305706Permeability across basolateral side at pH 6.5 to apical side at pH 7.4 in human Caco2 cells at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1668041Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID172558Maximal change in heart rate (HR) measured as % change from pretreatment value at dose of 5 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID176732Dose required for inhibition of isoproterenol-induced tachycardia in pithed rat after intravenous administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1220986Extraction ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1221018Intrinsic elimination clearance in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID180107TMaximal change in heart rate (HR) measured as pretreatment value at dose of 5 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1668034Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID172560Maximal change in mean arterial blood pressure (MABP) measured as % change from pretreatment value at dose of 10 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID180616Change in Heart rate(beats/min) was determined after 3h of (10 mg/kg p.o.) administration in conscious, spontaneously hypertensive rats1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1668042Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID26561compound was evaluated for rate constant of transfer (log K1) at pH 4.61998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID171746Change in blood-pressure was determined after 1 hr administration of (10 mg/kg/po) in conscious, spontaneously hypertensive rats(SHR)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1764401Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1764400Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36428The compound was evaluated for the antagonistic activity against alpha-1 adrenergic receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1764402Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1220970Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering fast binding process at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1668032Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID26549compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 8.81998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1737234Inhibition of human CYP1B1 at 5 uM using 7-ethyl-O-resorufin as substrate incubated for 30 mins in presence of NADPH by EROD assay2020European journal of medicinal chemistry, May-01, Volume: 193Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID33133Antagonism of the pressor response to phenylephrine (10 mg/kg iv) in anesthetized, normotensive rats was determined at a dose range 1-10 mg/kg1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221022Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering fast binding process at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID172551Maximal change in heart rate (HR) measured as % change from pretreatment value at dose of 10 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1636387Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 6.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID26546compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 4.61998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID180618Change in Heart rate(beats/min) was determined after 4 hr of (10 mg/kg p.o.) administration in conscious, spontaneously hypertensive rats1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID187453Relative potency required for inhibition of isoproterenol-induced tachycardia in pithed rat after intravenous administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID1212315Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence at 500 uM after 30 mins relative to control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID180614Change in Heart rate(beats/min) was determined after 2 hr of (10 mg/kg p.o.) administration in conscious, spontaneously hypertensive rats1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID172702Maximal change in mean arterial blood pressure (MABP) measured as % change from pretreatment value at dose of 5 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID738327Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by NMR analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
AID1220979Octanol-water apparent partition coefficient, logD of the compound at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID180101Maximal change in heart rate (HR) measured as pretreatment value at dose of 10 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1860217Apparent permeability across apical to basolateral side in human Caco-2 cells assessed as drug recovery at pH 6.5 to 7.42022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
AID1220982Extraction ratio of the compound in healthy Wistar rat perfused liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26288Partition coefficient (logD4.6)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID75210Beta-2-adrenoceptor ISA (intrinsic sympathomimetic activity)was measured as relaxant effect against a PGF2-alpha contracted guinea pig trachea at 1x10E-5 M1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID26564compound was evaluated for rate constant of transfer (log K1) at pH 8.81998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1305708Permeability across basolateral side at pH 6.5 to apical side at pH 7.4 in human Caco2 cells assessed as compound recovery at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID176747Dose required for inhibition of L-phenylephrine-induced pressor response in pithed rats after intravenous administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID1764399Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID180613Change in Heart rate(beats/min) was determined after 1 hr of (10 mg/kg p.o.) administration in conscious, spontaneously hypertensive rats1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1221014Intrinsic elimination clearance in healthy Wistar rat perfused liver assessed per gm of liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID732420Efflux ratio of permeability from basolateral to apical side over apical to basolateral in pig LLC-PK1 cells overexpressing human MDR1 relative to efflux ratio in parental cell line2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID187450Relative potency required for antihypertensive activity in spontaneous hypertensive rats after oral administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID171750Change in blood-pressure was determined after 3h administration of (10 mg/kg/po) in conscious, spontaneously hypertensive rats(SHR)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID738326Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by saturation transfer difference analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
AID1668035Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1211796Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID738328Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by surface plasmon resonance assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1764398Substrate activity at P-gp (unknown origin) assessed as net efflux ratio2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1211793Lipophilicity, log P of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1220976Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering slow binding process at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1220972Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering slow binding process at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID1221006Apparent distribution ratio of the compound in healthy Wistar rat perfused liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID186531Maximal change in mean arterial blood pressure (MABP) measured as pretreatment value at dose of 10 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID172555Maximal change in heart rate (HR) measured as % change from pretreatment value at dose of 25 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID168904Antagonistic activity was determined for 50% inhibition of tachycardia response in anesthetized, normotensive rat at a dose range of 0.1-1(iv)1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID186536Maximal change in mean arterial blood pressure (MABP) measured as pretreatment value at dose of 5 mg/kg in SHR1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1220998Permeability surface area product in healthy Wistar rat perfused liver assessed per gm of liver at 6 mM after 10 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,867)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901016 (54.42)18.7374
1990's329 (17.62)18.2507
2000's169 (9.05)29.6817
2010's255 (13.66)24.3611
2020's98 (5.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 107.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index107.70 (24.57)
Research Supply Index7.80 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index200.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (107.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials450 (22.73%)5.53%
Reviews174 (8.79%)6.00%
Case Studies260 (13.13%)4.05%
Observational8 (0.40%)0.25%
Other1,088 (54.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (54)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Acute Labetalol Use in Preeclampsia Randomized Trial [NCT03872336]Phase 415 participants (Actual)Interventional2019-02-18Terminated(stopped due to Slow enrollment)
Acute Control of Chronic Hypertension in Preeclampsia [NCT03877692]Phase 410 participants (Actual)Interventional2019-02-18Terminated(stopped due to Slow enrollment)
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II [NCT02281838]Phase 2270 participants (Anticipated)Interventional2011-08-01Recruiting
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04767061]Phase 49 participants (Actual)Interventional2021-04-01Completed
Randomized Controlled Trial for Postpartum Antihypertensive Treatment of Women With Preeclampsia [NCT04298034]Phase 3300 participants (Anticipated)Interventional2020-07-17Recruiting
Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial [NCT02531490]Phase 4368 participants (Anticipated)Interventional2015-01-01Recruiting
Outcome in Patients Treated With Intraarterial Thrombectomy - optiMAL Blood Pressure Control (OPTIMAL-BP) [NCT04205305]Phase 4306 participants (Actual)Interventional2020-06-18Active, not recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]1,600 participants (Anticipated)Observational2018-10-04Recruiting
Treatment of Elevated Blood Pressures in Early Pregnancy [NCT05955040]Phase 2234 participants (Anticipated)Interventional2023-07-11Recruiting
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial [NCT04343235]Phase 413 participants (Actual)Interventional2020-05-01Terminated(stopped due to Challenges with enrollment; primary investigator left the institution)
Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy [NCT03325348]Phase 2/Phase 3194 participants (Anticipated)Interventional2017-02-23Recruiting
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi. [NCT02050529]Phase 2190 participants (Actual)Interventional2012-10-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial [NCT00963976]Phase 274 participants (Actual)Interventional2007-01-31Completed
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH) [NCT05551104]500 participants (Anticipated)Interventional2023-12-31Recruiting
A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem [NCT01408524]Phase 1/Phase 2184 participants (Actual)Interventional2010-02-28Completed
[NCT00394537]Phase 472 participants (Anticipated)InterventionalCompleted
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF [NCT04757584]Phase 49 participants (Actual)Interventional2021-04-01Completed
[NCT01041066]70 participants (Anticipated)Interventional2009-09-30Recruiting
Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT) [NCT05139238]Phase 4104 participants (Anticipated)Interventional2023-08-01Not yet recruiting
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy [NCT01912677]Phase 4894 participants (Actual)Interventional2015-04-30Completed
Blood Pressure After Endovascular Stroke Therapy-II: A Randomized Trial [NCT04116112]Phase 2120 participants (Actual)Interventional2020-01-17Completed
Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial. [NCT01538875]Phase 3261 participants (Actual)Interventional2012-07-31Completed
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]Phase 34,587 participants (Actual)Interventional2012-03-31Completed
Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients [NCT03506724]Phase 4109 participants (Actual)Interventional2017-09-11Completed
Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management [NCT02426177]Phase 398 participants (Anticipated)Interventional2015-05-31Not yet recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]3,520 participants (Actual)Observational2011-11-30Completed
Changes in Central Arterial Pressure When Comparing Nifedipine and Labetalol for Routine Hypertension Control in Pregnancy [NCT02912910]0 participants (Actual)Observational2016-09-30Withdrawn(stopped due to PI withdrew protocol)
A Phase IV, Randomized Trial to Determine the Efficacy and Safety of Cardene Intravenous (I.V.) Versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting [NCT00765648]Phase 4226 participants (Actual)Interventional2008-10-31Completed
Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols [NCT02933593]0 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to PI withdrew the protocol)
A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke (HOPE Study) [NCT04892511]Phase 4814 participants (Anticipated)Interventional2021-06-01Recruiting
Treatment Targets for Chronic Hypertension in Pregnancy [NCT00194974]Phase 1/Phase 20 participants (Actual)Interventional2004-07-31Withdrawn(stopped due to Lack of funding)
A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage [NCT00226096]404 participants (Actual)Interventional2005-11-30Completed
Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke [NCT02327793]Phase 265 participants (Actual)Interventional2009-06-30Completed
Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. [NCT03809065]Phase 440 participants (Actual)Interventional2019-01-19Completed
Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) [NCT00293735]Phase 2/Phase 30 participants (Actual)Interventional2015-06-30Withdrawn(stopped due to Lack of funding)
Effects of Magnesium Sulfate and Labetalol Infusion Used for Induced Hypotension on Peripheral Perfusion and Postoperative Pain in Nasal Surgeries [NCT04688203]Phase 1/Phase 250 participants (Actual)Interventional2021-02-01Completed
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Blood Loss, Surgeon Visibility, Hemodynamic Parameters, and Operation Time During Orthognathic Surgery [NCT06093893]Phase 490 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Effects of Labetalol on Human Cocaine Use [NCT00000291]Phase 20 participants Interventional1997-10-31Completed
Effects of Labetalol on Nicotine Administration in Humans [NCT00000297]Phase 20 participants Interventional1998-10-31Completed
Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension [NCT02168309]50 participants (Actual)Interventional2014-06-30Completed
Randomized, Double-Blinded, Active-Controlled Study to Evaluate the Intraoperative Use of Labetalol vs. Esmolol for Maintaining Hemodynamic Stability During Laparoscopic Surgery: Effect on Recovery and Postoperative Pain [NCT01114971]Phase 475 participants (Actual)Interventional2009-09-03Completed
Department of Anestheia and Intensive Care Unit,Cairo University [NCT03059316]Early Phase 140 participants (Actual)Interventional2016-06-10Completed
Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia [NCT05310929]200 participants (Actual)Interventional2019-08-28Completed
The Effect of Intraoperative Labetalol on Time to Discharge and Hemodynamic Stability in Laparoscopic Cholecystectomy [NCT02997800]Phase 2172 participants (Actual)Interventional2012-11-30Completed
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial [NCT05309460]Phase 4600 participants (Anticipated)Interventional2022-06-06Not yet recruiting
The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy [NCT04755764]60 participants (Anticipated)Observational2021-03-03Recruiting
Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial [NCT03661346]Phase 228 participants (Actual)Interventional2017-03-01Completed
Blood Pressure Management in Stroke Following Endovascular Treatment [NCT04484350]Phase 230 participants (Actual)Interventional2020-10-23Completed
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia in Obese Patients [NCT03105661]Early Phase 1400 participants (Anticipated)Interventional2017-04-04Recruiting
An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage. [NCT00716079]2,839 participants (Actual)Interventional2008-09-30Completed
Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries? A Randomized Clinical Trial. [NCT05368376]Phase 460 participants (Actual)Interventional2021-04-01Completed
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia [NCT03245970]Early Phase 10 participants (Actual)Interventional2017-04-24Withdrawn(stopped due to Investigator retired. Other investigators did not want to continue study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00716079 (2) [back to overview]A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
NCT00716079 (2) [back to overview]Death at 90 Days
NCT00765648 (6) [back to overview]Treatment Failure
NCT00765648 (6) [back to overview]Transition Time to Oral Medication
NCT00765648 (6) [back to overview]Subjects Requiring the Use of Intravenous Rescue Medications
NCT00765648 (6) [back to overview]Percentage of Subjects Achieving a Pre-defined Target Systolic Blood Pressure (BP) Within 30 Minutes.
NCT00765648 (6) [back to overview]Emergency Department(ED)Time to Disposition Decision
NCT00765648 (6) [back to overview]Average Number of Dose Titrations Within 30 Minutes
NCT01114971 (6) [back to overview]Patient Satisfaction Using a Verbal Rating Scale From 0 to 10
NCT01114971 (6) [back to overview]Return to Feeling Normal
NCT01114971 (6) [back to overview]Postoperative Pain
NCT01114971 (6) [back to overview]Postoperative Nausea and Vomiting
NCT01114971 (6) [back to overview]Number of Participant With Opioid Consumption
NCT01114971 (6) [back to overview]Low Appetite
NCT02168309 (2) [back to overview]Total Length of Hospital Stay in Days
NCT02168309 (2) [back to overview]Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication
NCT03506724 (3) [back to overview]Time to Achieve Non Severe Range Blood Pressure
NCT03506724 (3) [back to overview]Number of Participants to Achieve Non Severe Range Blood Pressure
NCT03506724 (3) [back to overview]Number of Participants With Medication Side Effects
NCT03661346 (5) [back to overview]Average Heart Rate
NCT03661346 (5) [back to overview]Intra-operative Surgical Visibility - Boezaart Scale
NCT03661346 (5) [back to overview]Intra-operative Surgical Visibility - Wormald Scale
NCT03661346 (5) [back to overview]Rate of Blood Loss
NCT03661346 (5) [back to overview]Average Mean Arterial Blood Pressure
NCT04116112 (5) [back to overview]Utility-weighted Modified Rankin Score
NCT04116112 (5) [back to overview]Number of Participants With Symptomatic Hemorrhagic Transformation
NCT04116112 (5) [back to overview]Number of Participants With Neurological Worsening Associated With Antihypertensive Treatment
NCT04116112 (5) [back to overview]Number of Participants With Any Hemorrhagic Transformation
NCT04116112 (5) [back to overview]Final Infarct Volume
NCT04343235 (7) [back to overview]Breastfeeding Status
NCT04343235 (7) [back to overview]Change of Gestational Hypertensive Disorder Symptoms (Systolic BP)
NCT04343235 (7) [back to overview]Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure)
NCT04343235 (7) [back to overview]Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP)
NCT04343235 (7) [back to overview]Hospital Readmission
NCT04343235 (7) [back to overview]Hospital Length of Stay
NCT04343235 (7) [back to overview]Change of Dose for Antihypertensive Therapy
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.
NCT04767061 (10) [back to overview]Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)
NCT04767061 (10) [back to overview]Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)
NCT04767061 (10) [back to overview]Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT04767061 (10) [back to overview]Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)
NCT04767061 (10) [back to overview]Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device
NCT04767061 (10) [back to overview]Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)
NCT04767061 (10) [back to overview]Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering719
Guideline-Recommended Blood-Pressure Lowering785

[back to top]

Death at 90 Days

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering166
Guideline-Recommended Blood-Pressure Lowering170

[back to top]

Treatment Failure

Treatment failure is defined as admission to the hospital or observation unit for BP management (NCT00765648)
Timeframe: 6 hours

Interventionpercentage of participants (Number)
Nicardipine43.1
Labetalol37.4

[back to top]

Transition Time to Oral Medication

The median transition time (in hours) to oral medication (NCT00765648)
Timeframe: 6 hours

Interventionhours (Median)
Nicardipine4.9
Labetalol6.4

[back to top]

Subjects Requiring the Use of Intravenous Rescue Medications

The percent of subjects requiring the use of intravenous rescue medications (NCT00765648)
Timeframe: 6 hours

Interventionpercentage of participants (Number)
Nicardipine15.5
Labetalol22.4

[back to top]

Percentage of Subjects Achieving a Pre-defined Target Systolic Blood Pressure (BP) Within 30 Minutes.

Percentage of subjects achieving a pre-defined target systolic blood pressure (BP) range defined as a systolic blood pressure that is within +/- 20 mmHg of the target as established by the investigator. (NCT00765648)
Timeframe: 30 minutes after initiation of therapy

Interventionpercentage of participants (Number)
Nicardipine91.7
Labetalol82.5

[back to top]

Emergency Department(ED)Time to Disposition Decision

Median number of hours from hospital admission until Emergency Department(ED)disposition (NCT00765648)
Timeframe: 6 hours

Interventionhours (Median)
Nicardipine4.6
Labetalol4.6

[back to top]

Average Number of Dose Titrations Within 30 Minutes

Calculated as the mean (± standard deviation) number of titrations over 30 minutes for each treatment group (NCT00765648)
Timeframe: 30 minutes

Interventionnumber of titrations (Mean)
Nicardipine2.2
Labetalol1.3

[back to top]

Patient Satisfaction Using a Verbal Rating Scale From 0 to 10

Patient satisfaction using a verbal rating scale from 0 to 10 Where a VRS is a subjective measure in which individuals verbally rated their level of satisfaction on an eleven-point numerical scale. The scale is composed of 0 (excellent satisfaction) to 10 (NCT01114971)
Timeframe: 1 month

Interventionscore on a scale (0-10) (Mean)
Fentanyl9.1
Labetalol9
Esmolol8

[back to top]

Return to Feeling Normal

Days to report to return to feeling normal, using follow up questionnaires (NCT01114971)
Timeframe: 1 month

InterventionDays (Mean)
Fentanyl11
Labetalol10
Esmolol12

[back to top]

Postoperative Pain

Postoperative pain will be measured at PACU using a Verbal Rating Scale (VRS) from 0 to 10 VRS is a subjective measure in which individuals verbally rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain) (NCT01114971)
Timeframe: one day

InterventionScore on scale 0-10 (Mean)
Fentanyl3.2
Labetalol3
Esmolol3.9

[back to top]

Postoperative Nausea and Vomiting

Nausea and vomiting will be measured at PACU (NCT01114971)
Timeframe: 1 day

Interventionparticipants (Number)
Fentanyl9
Labetalol4
Esmolol7

[back to top]

Number of Participant With Opioid Consumption

n=Post discharge use of opioid consumption NUMBER OF PARTICIPANTS WHO TOOK PAIN KILLER PILLS (NCT01114971)
Timeframe: 1 month

Interventionparticipants (Number)
Fentanyl15
Labetalol14
Esmolol13

[back to top]

Low Appetite

Participant who experienced low appetite (follow up questionnaire) (NCT01114971)
Timeframe: 1 month

Interventionparticipants (Number)
Fentanyl15
Labetalol7
Esmolol9

[back to top]

Total Length of Hospital Stay in Days

Secondary outcome (NCT02168309)
Timeframe: 0-10 days

Interventiondays (Mean)
Labetalol4.0
Nifedipine4.3

[back to top]

Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication

Primary outcome (NCT02168309)
Timeframe: 24 hours

Interventionhours (Mean)
Labetalol37.6
Nifedipine38.2

[back to top]

Time to Achieve Non Severe Range Blood Pressure

Time to achieve goal blood pressure, that is, non severe range blood pressures after medication received. (NCT03506724)
Timeframe: Ten minute intervals from the time of the first severe range blood pressure, up to 1 hour

Interventionminutes (Median)
Intravenous Labetalol10
Oral Nifedipine20

[back to top]

Number of Participants to Achieve Non Severe Range Blood Pressure

Number of participants by ethnicity to achieve goal blood pressure, that is, non severe range blood pressures after medication received. (NCT03506724)
Timeframe: up to 1 hour

,
InterventionParticipants (Count of Participants)
White, Asian, and HispanicBlack
Intravenous Labetalol3318
Oral Nifedipine3122

[back to top]

Number of Participants With Medication Side Effects

Number of participants with side effect profile to assess the rate of side effects from IV labetalol and oral nifedipine (NCT03506724)
Timeframe: assessed 10 minutes to 1 hour after medication is given

,
InterventionParticipants (Count of Participants)
HeadacheNauseaVomitingDizzinessFlushingAny of the above
Intravenous Labetalol6328718
Oral Nifedipine10734715

[back to top]

Average Heart Rate

units of beats per minute, measured throughout the operation (NCT03661346)
Timeframe: Duration of operation up to 3 hours/completion of surgery

Interventionbpm (Mean)
Esmolol72
Labetalol69

[back to top]

Intra-operative Surgical Visibility - Boezaart Scale

"Standardized scoring systems used by surgeons to rate surgical field quality in FESS:~Boezaart scale (0-5):~0 = no bleeding (optimal)~= slight bleeding with no suction required~= slight bleeding with occasional suctioning required~= slight bleeding with frequent suctioning required~= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed~= severe bleeding (worst) with constant suctioning required and compromised view" (NCT03661346)
Timeframe: Duration of operation

Interventionscore on a scale (Mean)
Esmolol3.1
Labetalol3.1

[back to top]

Intra-operative Surgical Visibility - Wormald Scale

"Standardized scoring systems used by surgeons to rate surgical field quality in FESS:~Wormald scale (0-10):~0 = No bleeding (optimal)~= 1-2 points of blood ooze~= 3-4 points of ooze~= 5-6 points of ooze~= 7-8 points of ooze~= 9-10 points of ooze~= >10 points of ooze, obscuring field~= Mild field bleeding with slow post-nasal accumulation~= Moderate field bleeding with moderate post-nasal accumulation~= Moderate-severe field bleeding with rapid post-nasal accumulation~= Severe bleeding (worst) with nose filling rapidly" (NCT03661346)
Timeframe: Duration of operation up to 3 hours

Interventionscore on a scale (Mean)
Esmolol6.1
Labetalol5.9

[back to top]

Rate of Blood Loss

milliliters per minute (NCT03661346)
Timeframe: Duration of operation up to 3 hours

InterventionmL/min (Mean)
Esmolol.59
Labetalol.66

[back to top]

Average Mean Arterial Blood Pressure

units of mmHg, measured throughout operation (NCT03661346)
Timeframe: Duration of operation up 3 hours/completion of operation

InterventionmmHg (Mean)
Esmolol79.7
Labetalol79.4

[back to top]

Utility-weighted Modified Rankin Score

"Modified Rankin score (mRS) is a scale for measuring the degree of disability or dependence of people who have suffered a stroke. 0 - no symptoms at all; 1 - no significant disability despite symptoms; able to carry out all usual duties and activities; 2- slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- moderate disability; requiring some help, but able to walk without assistance; 4 - moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5 - severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- dead.~Patient centered utility weights are applied to these scores as 1.0 for mRS level 0; 0.91 for mRS level 1; 0.76 for mRS level 2; 0.65 for mRS level 3; 0.33 for mRS level 4; 0 for mRS level 5; and 0 for mRS level 6. Unlike the mRS, the utility-weighted mRS runs from 0 to 1, with 0 being the worst." (NCT04116112)
Timeframe: 90 days after treatment initiation

Interventionunits on a scale (Range 0-1; 1=best) (Mean)
Higher Systolic Blood Pressure (SBP) Target0.58
Lower SBP (<160 mmHg) Target0.47
Lower SBP (<140mmHg) Target0.51

[back to top]

Number of Participants With Symptomatic Hemorrhagic Transformation

Defined as number of participants with any new bleeding within the infarcted brain tissue and an NIH Stroke Scale worsening of 4 or more points associated with the bleeding within 36 (+/-12) hrs of treatment initiation (NCT04116112)
Timeframe: 36(+/-12) hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target2
Lower SBP (<160 mmHg) Target1
Lower SBP (<140mmHg) Target2

[back to top]

Number of Participants With Neurological Worsening Associated With Antihypertensive Treatment

Defined as number of participants with 4 points of greater increase in NIH Stroke scale associated with reduction in SBP caused by anti-hypertensive treatment initiation or titration. (NCT04116112)
Timeframe: Treatment initiation to 24 hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target0
Lower SBP (<160 mmHg) Target0
Lower SBP (<140mmHg) Target0

[back to top]

Number of Participants With Any Hemorrhagic Transformation

Number of participants with any new bleeding within the infarcted brain tissue on 36(+/-12) hr MRI/CT scan after treatment initiation (NCT04116112)
Timeframe: 36(+/-12) hrs after treatment initiation

InterventionParticipants (Count of Participants)
Higher Systolic Blood Pressure (SBP) Target12
Lower SBP (<160 mmHg) Target12
Lower SBP (<140mmHg) Target14

[back to top]

Final Infarct Volume

Infarct volume on diffusion-weighted MRI (or CT if MRI cannot be obtained) at 36 (+/-12) hrs after treatment initiation, adjusted for the baseline CT perfusion core infract volume. (NCT04116112)
Timeframe: 36 (+/-12) hrs after treatment initiation

InterventionCubic Centimeters (Mean)
Higher Systolic Blood Pressure (SBP) Target46.4
Lower SBP (<160 mmHg) Target50.7
Lower SBP (<140mmHg) Target32.4

[back to top]

Breastfeeding Status

breastfeeding continuation after discharge (NCT04343235)
Timeframe: at 1 week postpartum visit

InterventionParticipants (Count of Participants)
Labetalol + Furosemide1
Labetalol Only3

[back to top]

Change of Gestational Hypertensive Disorder Symptoms (Systolic BP)

average systolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average systolic blood pressure for Day 0, Day 1, and Day 2

,
Interventionmm of mercury (Mean)
Day 0Day 1Day 2
Labetalol + Furosemide138.4134.9135.2
Labetalol Only138.1138.2136.7

[back to top]

Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure)

average mean arterial pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average mean arterial pressure on Day 0, Day 1, and Day 2

,
Interventionmm of mercury (Mean)
Day 0Day 1Day 2
Labetalol + Furosemide102.499.598.0
Labetalol Only100.0100.196.0

[back to top]

Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP)

average diastolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average diastolic blood pressure on Day 0, Day 1, and Day 2

,
Interventionmm of mercury (Mean)
Day 0Day 1Day 2
Labetalol + Furosemide84.181.878.8
Labetalol Only80.180.775.5

[back to top]

Hospital Readmission

readmission for hypertension management (NCT04343235)
Timeframe: up to 14 days after discharge

InterventionParticipants (Count of Participants)
Labetalol + Furosemide1
Labetalol Only2

[back to top]

Hospital Length of Stay

days in hospital after delivery (NCT04343235)
Timeframe: Number of days of hospital stay from randomization to discharge

Interventiondays (Mean)
Labetalol + Furosemide3.5
Labetalol Only4.3

[back to top]

Change of Dose for Antihypertensive Therapy

number of patients who require a change in the dose of labetalol to control BP (NCT04343235)
Timeframe: Change in dose of hypertensive therapy from randomization until hospital discharge (up to 7 days)

InterventionParticipants (Count of Participants)
Labetalol + Furosemide3
Labetalol Only0

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Balance Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The balance test portion of the SPPB assesses the subject's ability to stand unassisted without the use of a cane or walker. Balance test scores range from 0 - 4 with higher scores indicating better ability to stand unassisted. Our research team conducted the balance test according to SPPB standards. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers3.9
OFF Beta Blockers3.6

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Chair Rise Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The chair rise portion of the SPPB assesses core strength. When comparing the number of seconds it takes to complete 5 chair rises, quicker speeds indicate better core strength. Our research team has chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers16
OFF Beta Blockers15.1

[back to top]

Change in Lower Extremity Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by the Gait Speed Portion of a Modified Version of the Short Physical Performance Battery.

"The Short Physical Performance Battery assesses gait speed, core strength when rising from a chair without using the upper extremities, and balance while standing without a cane or walker. The gait speed portion of the SPPB assesses the subject's lower extremity function. When comparing the number of seconds it takes to complete the 4-meter gait speed test, quicker speeds indicate better lower extremity function. Our research team conducted the 4-meter gait speed test according to SPPB standards, but have chosen on comparing the speed at which subjects were able to complete the test. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionseconds (Mean)
ON Beta Blockers4.3
OFF Beta Blockers4.6

[back to top]

Change in Patient-reported Cognitive Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a)

"Patient-Reported Outcome Measurement Information System-Short Form 6a (PROMIS SF-6a) is a survey of patient-perceived cognitive deficits. Questions are ranked on a 5-point Likert scale, with higher scores indicating better cognitive function. Scores are mapped so the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse cognitive function compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3-6 weeks. The outcome measure data is the mean of the data collected during the span of the measured time points." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers53.8
OFF Beta Blockers52.4

[back to top]

Change in Patient-reported Health When on Beta-blocker Versus When Off Beta-blocker, as Measured by the EuroQol-5D Visual Analogue System (EQ-5D VAS)

"The EuroQol-5D Visual Analogue System (EQ-5D VAS) indicates patient-perceived health on a vertical visual analogue scale. The scale ranges from 0, indicating poorest health, to 100, indicating the best health. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 24-weeks. This outcome was measured at baseline and at each end of period visit.

Interventionscore on a scale (Mean)
ON Beta Blockers68.9
OFF Beta Blockers67.8

[back to top]

Change in Patient-reported Health Status When on Beta-blocker Versus When Off Beta-blocker, as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ-12)

"The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a heart failure-specific health status survey. Questions are ranked on 5- to 7-point Likert scales, with higher scores indicating better health status. KCCQ scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The max amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, bi-weekly, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers58.7
OFF Beta Blockers66.0

[back to top]

Change in Patient-reported Quality of Life When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-29 (PROMIS-29)

"The PROMIS-29 assesses 7 domains with 4 questions with an additional pain intensity numeric rating scale. The patients' answers to the PROMIS-29 are scored from 1-5 (except for the pain numeric rating scale). The sum of the PROMIS-29 is the raw score transformed into a final T-score metric. Scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and an SD of 10. Instead of having a min or max, the PROMIS-29 raw scores have been transformed into t-scores for comparison to a reference population (the US general population) with a mean of 50 and SD of 10. Scores lower than 50 indicate worse health compared to the US general population. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker before enrollment, therefore, each subject's respective period for the OFF and ON periods could range between 3 - 6 weeks. The values measured over the time points were averaged." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, weekly, end of period and intervention visits, and during follow-up.

,
Interventionscore on a scale (Mean)
Physical Health ComponentMental Health Component
OFF Beta Blockers40.047.9
ON Beta Blockers39.846.8

[back to top]

Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device

"The wearable activity monitoring device measures daily step count. Due to the nature of N-of-1 trials, the duration of a subject's periods varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 and 6 weeks. We will compare average step counts over 2-week periods, which will be the final 2 weeks of each period when subjects are either on their home (ON Beta Blockers) or minimally tolerated (OFF Beta Blockers) dose. The outcome measure data is the mean collected during the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 8-weeks (last 2 weeks of each period for up to 4 periods).

InterventionCount of Steps (Mean)
ON Beta Blockers2790.5
OFF Beta Blockers3167.3

[back to top]

Change in Exercise Capacity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Peak Oxygen Consumption (VO2) During Cardiopulmonary Exercise Test (CPET)

"Cardiopulmonary exercise testing (CPET) measures breath-by-breath oxygen production during symptom-limited exercise on a stationary bike. This permits the calculation of peak oxygen consumption (VO2). Percent predicted peak VO2 for body weight will also be calculated. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this outcome measure is 6-weeks. This outcome was measured at the end of the first and second visit.

Interventionml/kg/min (Mean)
ON Beta Blockers10.0
OFF Beta Blockers11.4

[back to top]

Change in Patient-reported Sexual Function When on Beta-blocker Versus When Off Beta-blocker, as Measured by Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function)

"Patient-Reported Outcome Measurement Information System-Sexual Function (PROMIS-Sexual Function) measures self-reported sexual function and satisfaction. Questions are ranked on a 6-point Likert scale, with higher scores indicating poorer sexual function and satisfaction. Due to the nature of N-of-1 trials, the duration of a subject's period varies based on the subject's home dose of beta-blocker prior to enrollment, therefore, each subject's respective time period for the OFF and ON periods could range between 3 - 6 weeks. The outcome measure data is the mean of the data collected during the span of the outcome measure time frame. The score ranges from 0-10 with higher scores meaning worsened sexual function." (NCT04767061)
Timeframe: The maximum amount of time a subject could have been assessed for this measure is 76-weeks (24-week max intervention phase,1-year follow-up phase). This outcome was measured at baseline, end of period and intervention visits, and during follow-up.

Interventionscore on a scale (Mean)
ON Beta Blockers1.8
OFF Beta Blockers2.1

[back to top]